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The search for effective drugs treating diseases has been an age-old quest. While 
drug design and development have witnessed major progress over the last decades, one of 
the main challenges still resides in the lack of efficacy. Consequently, traditional lead 
selection procedures like Lipinski’s rule of five and affinity-based selection need to be 
reconsidered. Over the past 10-years, binding kinetics, i.e. the association and dissociation 
rate of a drug to and from its target, have been proposed as better predictive parameters in 
assessing the potential of novel drugs [1-6]. Although the importance of binding kinetics is 
increasingly recognized, there is still a need for robust assays suitable to study association 
and dissociation rates of potential drug candidates. Additionally, many successful drugs 
achieve their effect by competing with endogenous ligands for the same binding site. 
Therefore, understanding the pharmacological and physiological behavior, such as binding 
kinetics, of endogenous ligands in the human body is crucial. This is of particular importance 
for endogenous ligands since they are often released temporally at locally high 
concentrations. Finally, to bridge the gap between in vitro and in vivo studies, functional 
assays that can reliably translate binding kinetics to in vitro functional effects are crucial. 
To illustrate the importance and relevance of the research performed in this thesis, 
this chapter provides a general introduction. Firstly, the superfamily of G protein-coupled 
receptors (GPCRs) will be introduced, followed by an introduction of the sub-family of 
neuropeptide receptors which are predominantly GPCRs. Consequently, the background of 
two well-known neuropeptide receptors, namely the gonadotropin-releasing hormone 
(GnRH) receptor and neurokinin 1 (NK1) receptor, will be outlined as the experimental 
chapters of this thesis are centered around these receptors. Furthermore, the concept of 
binding kinetics will be defined, including the challenges of measuring these kinetic binding 
parameters. Lastly, the aim and outline of this thesis will be explained.   
G protein-coupled receptors  
 The GPCR family is one of the largest and most diverse receptor families and nearly 
800 genes encoding GPCRs have to date been identified [7]. GPCRs are composed of 
seven transmembrane helices with extracellular and intracellular loops and an extracellular 
(N-terminal) and intracellular (C-terminal) tail. GPCRs are coupled to intracellular G proteins 
and can be activated by a wide range of ligands, such as peptides, neurotransmitters, 
hormones, growth factors, odorant molecules and even photons [8] (Figure 1). GPCR 
activation results in a conformational change of the receptor, causing GDP to be exchanged 
for GTP. Consequently, this leads to dissociation of the Gαβγ-heterotrimer into the βγ-dimer 
and the α-subunit. The four main Gα-subunits are; Gαi, Gαs, Gαq and Gα12/13. The activation 
and inhibition of diverse G protein-dependent pathways makes GPCRs essential in cell 
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signaling [9]. Targeting the GPCR super-family has led to approximately 30% of the 
marketed drugs and to date GPCRs are vital targets in drug research due to their role in 
(patho-) physiology throughout the body [10]. 
 
Figure 1: Schematic overview of ligands binding to G protein-coupled receptors and their 
four main signaling pathways. A wide range of ligands can bind and activate GPCRs through 
G protein-dependent (i.e. Gαs, Gαq, Gαi and Gα12 proteins) and G protein-independent (e.g. 
β-arrestin) pathways. These signaling pathways can regulate pivotal cellular functions such 
as proliferation [8].   
 
Neuropeptide receptors  
 Neuropeptides are (poly)peptides and can be short as kisspeptin-10 (e.g. 3 amino 
acids) or as long as neurexophilin-1 (e.g. 250 amino acids). Neuropeptides mediate neuronal 
communication by binding to neuropeptide receptors expressed on either neuronal 
substrates such as glial cells or on non-neuronal target cells [11]. The neuropeptide receptor 
family consists of over 44 receptor families which are predominantly GPCRs. Neuropeptide 
receptors and their endogenous ligands are involved in numerous behavioral and 
physiological functions such as blood pressure, body temperature, feeding behavior, pain 
regulation, reproduction, learning, memory and sleep [12]. Consequently, neuropeptide 
transmission is an attractive focal area for drug design in numerous therapeutic areas, such 




 One of the most well-known neuropeptide receptors is the gonadotropin-releasing 
hormone (GnRH) receptor. This receptor binds endogenous GnRH and upon activation 
stimulates the production of follicle stimulating hormone (FSH) and luteinizing hormone (LH). 
The GnRH receptor belongs to the superfamily of GPCRs and is (predominantly) coupled to 
Gαq/11 proteins This receptor is involved in maintaining hormone levels in both males and 
females which makes it an attractive drug target in the treatment of hormone-dependent 
diseases such as fertility disorders, precocious puberty, and cancers of the endometrium, 
ovary, prostate and mammary [16, 17]. Sustained receptor exposure to GnRH or GnRH 
analogs leads to desensitization of GnRH receptor-mediated gonadotropin secretion. This 
desensitization or blockade of the GnRH receptor is called chemical castration and underlies 
the therapeutic use of GnRH analogs. The first GnRH analog to reach the market was 
nafarelin acetate in 1998 and soon after many more GnRH analogs were FDA approved, 
such as leuprolide acetate, goserelin acetate, degarelix  and triptorelin [18-20]. To date, 
many peptide GnRH receptor agonists and antagonists are on the market to treat hormone-
dependent disorders [17, 21-24] and available patient information suggest that the 
pharmacokinetic and pharmacodynamic profiles are very comparable. Accordingly, insights 
into the in vitro binding parameters, such as drug-target binding kinetics, could improve the 
understanding of the mechanism of action of these well-known drugs. 
 
NK1 receptor 
 Another well-known neuropeptide receptor is the neurokinin 1 (NK1) receptor or 
tachykinin 1 receptor. This receptor belongs to the tachykinin receptor family that consists of 
NK1, NK2 and NK3 receptors. The NK1 receptor belongs to class A GPCRs and is 
functionally coupled to Gαq/11 proteins and Gαs proteins. Multiple endogenous tachykinins 
bind to the NK1 receptor, including Substance P (SP), neurokinin A (NKA) and neurokinin B 
(NKB). Each tachykinin has a specific rank order to activate tachykinin receptors with regard 
to potency and affinity, namely SP > NKA > NKB for the NK1 receptor, NKA > NKB > SP for 
the NK2 receptor and NKB > NKA > SP for the NK3 receptor. The NK1 receptor plays an 
imperative role in the brain with respect to the regulation of affective behavior and emesis, as 
well as nociception in the spinal cord [25].   
Presently, only two drugs are on the market targeting the NK1 receptor for the 
treatment of chemotherapy-induced nausea and vomiting (CINV). Aprepitant, a high affinity, 
selective NK1 receptor antagonist was FDA approved in 2003 [26]. This small molecule 
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antagonist was the first NK1 antagonists to reach the market as previous clinical trials were 
predominantly aimed towards clinical pain states [27]. Interestingly, a distinguishing feature 
of aprepitant is its so-called PK/PD discrepancy in vivo, i.e. aprepitant levels in the brain 
were below the limit of quantification while a strong inhibitory effect was still present, which 
researchers attest to its slow receptor dissociation rate [28]. In 2014, a combination drug of a 
NK1 small molecule antagonist (netupitant) and a 5-HT3 antagonist, was approved for the 
treatment of CINV [29]. In vitro studies demonstrated that netupitant was wash-out resistant 
for up to 5 hours and the action of netupitant was therefore deemed insurmountable [30]. 
These two drug examples allude to the importance of being aware of and consequently 
optimizing kinetic binding parameters.  
Binding kinetics, a retrospective analysis 
Traditional drug discovery programs are predominantly focused on equilibrium-based 
parameters such as Ki and IC50 values. However, candidate drugs with high affinity and 
potency often fail in clinical trials due to target toxicity and/or lack of in vivo efficacy [31, 32]. 
Therefore, other, more predictive parameters than affinity and potency values are warranted. 
Binding kinetics are a collective term for the association (kon) and dissociation (koff) rate 
constant of a drug to and from its target. Additionally, the so-called drug-target residence 
time is reflective of the life-time of the drug-target complex and is defined as the reciprocal of 
koff [3]. Over the past 10 years binding kinetics are increasingly acknowledged to be vital for 
the mechanism of action of a potential drug [33]. Moreover, many blockbuster drugs have 
been retrospectively been examined for their binding kinetics and were found to have distinct 
kinetic profiles [34]. For example, quetiapine, a dopamine D2 receptor antagonist approved 
for the treatment of schizophrenia and bipolar disorder, has significantly less adverse effects 
and on-target toxicity in comparison to other dopamine D2 receptor antagonists due to its fast 
dissociation rate [35]. However, more often slow dissociation rates are favorable. Tiotropium, 
a muscarinic M3 receptor antagonist, is a well-known long-acting muscarinic antagonist. 
Since the muscarinic M3 receptor is mainly targeted to treat chronic diseases, a long duration 
of action is desirable to achieve prolonged efficacy and thus improve patient compliance [36]. 
Another advantage, aside from the long duration of action of tiotropium, is that it has kinetic 
selectivity (i.e. faster dissociation rates from other muscarinic receptor subtypes) over other 
muscarinic receptors thereby minimizing off-target toxicity [37]. Finally, negative allosteric 
CCR5 modulator maraviroc, was the first drug targeting CCR5 to get FDA approval and 
proved to be highly efficacious in inhibiting HIV cell infection[38]. Watson and colleagues 
reported very slow dissociation rates for this compound and the reversal of antagonism rate 
was found to be longer than 136 hours at room temperature [39]. All these case studies 
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demonstrate the importance of binding kinetics in achieving high in vivo efficacy and/or 
minimizing (target) toxicity. 
Challenges of incorporating binding kinetics in the drug discovery paradigm 
 While the previous examples greatly emphasize the impact of binding kinetics, kinetic 
binding parameters are often only taken into account in retrospect, if at all. Concerns are 
regularly expressed about suitable high-throughput assays to study binding kinetics in a time-
efficient manner, such that they might be introduced in an earlier stage of the drug discovery 
process. 
Labeled binding assays 
The most recognized assays to study binding kinetics are radioligand binding 
experiments, where the ligand of interest is radiolabeled and association and dissociation 
experiments are performed to directly measure kon and koff values. However, since 
radiolabeling every potential drug candidate is very costly and time consuming, novel 
protocols and techniques have been proposed over the past years [34, 40].  
In 1984, Motulsky and Mahan introduced a pharmacological approach in which the 
binding kinetics of unlabeled ligands can be quantitatively measured by only using one 
labeled tracer[41]. This so-called competition association method has to date been used to 
determine the binding kinetics of numerous potential drug candidates [42-44]. Recently, a 
more medium-throughput dual-point competition association assay was developed [45]. This 
assay makes use of only two time points and the specific binding of the labeled tracer at 
these time points generates a qualitative measure of the dissociation kinetics of the 
(competitive) unlabeled ligand. This screening assay has already been successfully applied 
to multiple targets [46-48].  
Considering the disadvantages of working with radioactivity, alternative labeling 
techniques have been explored. Schiele et al developed a universal homogeneous kinetic 
probe competition assay (kPCA) that allowed accurate and cost-effective measurements of 
binding kinetics in a high-throughput format [49]. They compared binding kinetics of three 
target groups (GPCRs, protein-protein interactions and enzymes) measured with radioligand 
binding studies, kPCA and surface plasmon resonance (SPR) spectroscopy. Results were 
highly correlated and the authors proposed that the time-resolved fluorescence energy 
transfer (TR-FRET) method used for kPCA combines the time resolution of SPR and related 
biosensors while maintaining the versatility of radioligand binding studies. Notably, one of the 
16 
 
disadvantages of kPCA is the need for not only a fluorescently labeled tracer but also an 
engineered fluorescently labeled receptor.  
Label-free binding assays 
Alternative methods to measure binding kinetics are label-free techniques such as 
SPR and surface acoustic wave (SAW) biosensors [50, 51]. These assays enable real-time 
quantitative measurements of association and dissociation rates of unlabeled ligands 
targeting membrane proteins. Advantages of both assays are the capability of using relatively 
small quantities of materials in addition to the high time resolution [52-54]. The need for 
having an immobilized receptor protein represents a serious disadvantage when studying 
GPCR binding as these proteins rapidly disintegrate when taken out of their natural 
environment. 
More recently, a label-free mass spectrometry (MS) ligand binding assay was 
developed for the adenosine A1 and A2A receptors [55]. The authors were able to perform 
saturation, association, dissociation and displacement studies without an internal standard 
making it a true label-free assay suitable to study binding kinetics. Results from the MS 
experiments were highly correlated to radioligand binding studies. An inconvenience of this 
assay is the need for an elaborate sample quantification procedure that needs technical 
expertise.     
Functional assays 
Another method to qualitatively study binding kinetics of agonists and antagonists is 
by measuring their functional effects.  
To examine the binding kinetics of agonists, a functional wash out can be conducted. 
Cells are pre-incubated with the agonist of interest to allow the binding of agonist to the 
receptor. Consequently, cells are washed and the effects of agonist binding can be 
measured. In theory, agonists with fast dissociation kinetics should be readily washed out 
while slowly dissociating agonists should still be bound to the receptor thereby maintaining 
most of the functional effect [56]. 
The binding kinetics of antagonists can be measured by examining their functional 
insurmountability. For these experiments cells are pre-incubated with a competitive 
antagonist prior to addition of an (endogenous) agonist. The maximal response of the agonist 
with and without antagonist pre-incubation can then be compared. If the maximal response of 
the agonist is significantly decreased upon antagonist pre-incubation, the antagonist is 
deemed insurmountable which is often correlated to its slow dissociation rate [57, 58]. A 
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drawback of functional assays predicting binding kinetics is that these only provide an 
indication for the dissociation rate of a ligand while the association rate might also be of 
importance.  
Objectives and outline of this thesis 
Objective  
The objective of this thesis was to provide kinetic binding parameters of well-known 
neuropeptides and competitive drugs targeting the GnRH receptor and NK1 receptor to 
advance the understanding of these ligand-receptor interactions. Additionally, we aimed to 
design, validate and compare various kinetic assays to supply a more diverse toolbox 
suitable for studying binding kinetics. The kinetic assays that were used and discussed in this 
thesis are radioligand binding, TR-FRET, label-free xCELLigence and real-time cAMP 
assays (Figure 2). Lastly, correlations between binding kinetics and functional effects in vitro 
were explored. A schematic overview of the contents of this thesis is presented in Figure 3.  
Outline 
In Chapter 2 the kinetic profile of neuropeptide – receptor interactions is reviewed to 
provide a clear overview of the importance of binding kinetics and other kinetic interactions. 
This chapter also includes the potential of neuropeptide receptors in drug discovery. 
Furthermore the relevance of not only characterizing the drug candidate but also the 
endogenous ligand and target, with particular focus on their kinetic aspects, is explained. 
The binding kinetics of well-known GnRH receptor agonists are analyzed in Chapter 
3. For this purpose two kinetic binding assays were designed, validated and compared 
(Figure 2A and 2B).  
Endogenous GnRH and a slowly dissociating analog (buserelin) were further studied 
in Chapter 4. The receptor activation profiles induced by both agonists were examined with a 
label-free impedance-based assay measuring changes in cell morphology (Figure 2C). This 
assay allowed for real-time measurements of cellular effects. A wash-out assay was also 








Figure 2: Schematic depiction of the kinetic binding assays (A and B) and kinetic functional 
assays (C and D) used in this thesis. (A) Radioligand binding assay. Assay requirements are cell 
membrane preparations and high affinity radiolabeled tracer. Over time the unlabeled ligand of 
interest will displace the radiolabeled tracer and from this the kon, koff and residence time (RT) 
values of the unlabeled ligand can be calculated. (B) TR-FRET™ assay. Assay requirements are 
whole cells with a SNAP-tagged receptor and a high affinity fluorescent tracer. When the 
fluorescent tracer and tagged receptor are in close proximity a FRET signal can be detected, over 
time the unlabeled ligand of interest will displace the fluorescent tracer and from this the  kon, koff 
and RT values of the unlabeled ligand can be calculated. (C) Real-time functional label-free 
xCELLigence assay. Assay requirements are whole cells, no tracer or labeling necessary. 
Receptor activation can be followed over time by monitoring the cell morphology through 
impedance. (D) Real-time functional GloSensor™ cAMP assay. Assay requirements are whole 
cells transfected with GloSensor plasmid, this cAMP-biosensor undergoes a conformational 
change upon cAMP binding, followed by the turnover of Luciferin resulting in an increase in 
luminescence. cAMP production can be followed over time by monitoring luminescence.  
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In Chapter 5 the binding kinetics of well-known endogenous tachykinins targeting the 
NK1 receptor are examined using radioligand binding studies (Figure 2A). Moreover, 
functional parameters such as potency and maximal response values were determined in 
label-free impedance-based experiments (Figure 2C). 
In Chapter 6 the relationship between in vitro drug-target binding kinetics and cellular 
responses is investigated to improve the understanding of drug efficacy in vivo. The 
functional effects of slowly (aprepitant) and fastly (DFA) dissociating NK1 receptor 
antagonists were examined in the 
presence of endogenous agonists SP 
or NKA. Two different kinetic 
functional assays were compared, 
namely a real-time morphology-based 
assay and a real-time cAMP assay 
(Figure 2C and 2D). Moreover, we 
examined the onset of receptor 
activation, providing a novel method 
to examine binding kinetics in a 
functional assay.  
Chapter 7 provides an overall 
conclusion of the novel findings 
presented in this thesis and new 
perspectives and opportunities for the 
research toward GPCRs, including 
neuropeptide receptors, and kinetic 
interactions are discussed. Hopefully 
this thesis will inspire researchers in 
academia and industry to implement 
kinetic binding studies to their 
research programs.  
  
 
Figure 3: Schematic overview of the contents of 
this thesis. The main focus of this thesis is on the 
binding kinetics (kon, koff and RT) of endogenous 
ligands and competitive drugs targeting the GnRH 
receptor or the NK1 receptor. Furthermore, the 
translation of these varying binding kinetics to in 
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Currently, drug discovery focusses only on quantifying pharmacological parameters, 
sometimes including binding kinetics, of drug candidates. For a complete understanding of a 
drug’s desired binding kinetics, the kinetics of both the target and its endogenous ligands 
should be considered. This is because the release and binding kinetics of endogenous 
ligands in addition to receptor internalization rates are significant contributors to drug-target 
interactions.  
Here, we discuss the kinetic profile of three neuropeptides and their receptors; 
gonadotropin-releasing hormone receptor (GnRHR), neuropeptide Y receptors, and 
corticotropin-releasing factor receptor 1 (CRF1R). These three examples provide new 
insights into the importance of kinetic profiles which could improve the understanding of 
desired drug-target binding kinetics and advance drug discovery for various neurological and 





Background of neuropeptides in drug discovery 
Over the past 40 years, many neuropeptides have been identified in the central 
nervous system (CNS) and the peripheral nervous system (PNS). Neuropeptides are 3-100 
amino acid long polypeptides and are synthesized by neurons. Neuropeptides act on either 
neural substrates, such as neurons and glial cells or on non-neuronal target cells [1]; they 
mediate neuronal communication by acting on neuropeptide receptors. Neuropeptide 
receptors include over 44 receptor families, of which most are G protein-coupled receptors 
(GPCRs). Neuropeptides and their cognate receptors are involved in many physiological and 
behavioral functions, such as pain regulation, blood pressure, body temperature, feeding 
behavior, reproduction, sleep, and learning and memory [2]. Therefore, neuropeptide 
transmission is an attractive area for drug discovery in several therapeutic areas, including 
inflammatory conditions [3], epilepsy [4] and psychiatric diseases [5]. Release of endogenous 
neuropeptides is often pulsatile or in bursts in response to stress, resulting in instant high 
local concentrations which adds complexity to the development of drugs targeting 
neuropeptide receptors [6].  
Optimized ligand-receptor binding kinetics is an emerging concept in drug 
discovery research 
Many drug candidates have failed in clinical trials, over 50% due to a reported lack of 
efficacy [7]. Several studies suggest that binding kinetics, particularly the lifetime of the 
ligand-receptor binary complex, may be more relevant for in vivo drug efficacy than their 
typical equilibrium parameters obtained in vitro, such as target affinity (Ki) and potency (IC50) 
[8-10]. This lifetime can be expressed as the drug-target residence time (RT) and is reflected 
by the dissociation rate constant (koff) of the ligand or drug. The koff value can simply be 
converted to RT, which is equal to the reciprocal of koff (RT = 1/koff).  
Currently, several successfully marketed drugs in the GPCR field have been proven 
in retrospect to have long RT [11]. These drugs illustrate the benefits of optimized binding 
kinetics in drug discovery represented by lower dosages, increased efficacy and/or safety. 
For example, the NK1 receptor antagonist aprepitant has superior in vivo efficacy in 
comparison to other NK1 receptor antagonists due to its slow receptor dissociation [11]. As 
another example, patients with asthma or chronic obstructive pulmonary disease (COPD) 
can benefit from the slowly dissociating β2-adrenoreceptor agonist olodaterol [12]. The 
bronchodilating effects of this drug last up to 24 h. which allows for once-daily administration. 
However, it is important to note that slow dissociation rates are not always desired. Long RT 
can also lead to adverse effects and thereby decrease drug safety in the patient [10]. An 
example of a successful drug with a short residence time is quetiapine, a dopamine D2 
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receptor antagonist approved for the treatment of schizophrenia and bipolar disorder. This 
antipsychotic drug was shown to have fewer (on-target) side effects than other dopamine D2 
receptor antagonists on the market [13]. Altogether, incorporating optimized binding kinetics 
prospectively could improve the success rate in drug discovery and development and thus of 
drugs entering the market.  
 
Figure 1.  Schematic representation of the structure of this review. Drugs are often 
competing with endogenous ligands but the kinetic profile of the target receptor and its 
endogenous ligand(s) are often overlooked. In this review the endogenous ligand release 
kinetics, endogenous ligand binding kinetics and receptor fate (e.g., internalization kinetics 
and degradation pathways), i.e. kinetic profiles, of three exemplary and diverse neuropeptide 
receptor classes and their endogenous ligands will be discussed. 
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The kinetic profile of a target receptor and its endogenous ligand 
The majority of successful drugs achieve their effect by competing with endogenous 
ligands for the same binding site. Therefore, understanding the pharmacological and 
physiological behavior of endogenous ligands in the human body is crucial. In contrast to the 
in vitro test tube situation, the human body is an open system. Consequently, the 
concentration of endogenous ligand, drug and target receptor change over time as these 
molecules enter and leave the system [10, 14]. Moreover, in order to comprehend desired 
drug-target kinetics, awareness of the kinetic profile of the target receptor and its 
endogenous ligand(s) is essential. Firstly, it is imperative to consider the time scale and rate 
of endogenous ligand release as this can result in temporarily high local concentrations. 
Secondly, knowledge of the rates of association to and dissociation from the receptor not 
only of the drug candidate but also of the endogenous ligand should be considered as these 
parameters can be a limitation to the availability of the unoccupied receptor. Finally, to get a 
better understanding of the in vivo effects of a drug candidate, insight into the rate at which 
receptors desensitize or internalize under normal and pathophysiological conditions is 
necessary [15]. Agonist responses are usually regulated by receptor desensitization and 
internalization and this can limit the effect and duration of receptor signaling [16]. Moreover, 
receptor complexation with receptor activity-modifying proteins (RAMPs) [17], as well as 
receptor ubiquitination and other degradation steps are of influence on receptor half-life [18] 
and although literature on this topic is sparse more knowledge could aid drug discovery [19]. 
Accordingly, the impact of a long RT drug may be diminished when receptors are rapidly 
degraded or recycled [15, 20]. Attempts to simultaneously address these aspects in 
mathematical models that allow such an in vitro/in vivo translation are encouraging. These 
models can be of great value to analyze experimental data and simulate various cases of 
drug treatment in a comprehensive and integrative fashion [21]. 
In brief, to improve drug discovery more insight towards the kinetic characteristics of 
both drug and the endogenous ligand and its target, i.e. the full kinetic profile, is crucial 
(Figure 1). We propose a new perspective to drug discovery, where increased attention is 
paid to 1) release frequency of endogenous ligands (Box 1, Box 2 and Figure 2), 2) binding 
kinetics of endogenous ligands, and 3) internalization and degradation rates of target 
receptors. To demonstrate the diversity in kinetic profiles of neuropeptide receptors, we 
provide a synthesis of the kinetic profiles of three exemplary and diverse neuropeptide 
receptors and their endogenous ligands, i.e. gonadotropin-releasing hormone receptor 
(GnRHR), neuropeptide Y receptors, and corticotropin-releasing factor receptor 1 (CRF1R) 




Kinetic profile of neuropeptide receptors and their endogenous ligands 
GnRH and the GnRHR 
Gonadotropin-releasing hormone (GnRH) is a neuropeptide that mediates the central 
control of the reproductive system and is released by the hypothalamus. GnRH activates 
GnRH receptors (GnRHRs) in the anterior pituitary and subsequently stimulates secretion of 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH). GnRH is released in high 
and low frequency pulses dependent on gender and reproductive cycles (Box 1 and Figure 
2) [24], and plasma concentrations range from 0.1-2.0 pg/ml (i.e. 84.5 nM – 1.7 µM) [25]. 
GnRHR belongs to the class A rhodopsin-like family of GPCRs and GnRHR is predominantly 
coupled to Gαq/11 proteins. A unique feature of the GnRHR is that it, unlike all other GPCRs, 
lacks an intracellular C-terminal tail [26]. GnRHR is successfully targeted to treat hormone-
dependent diseases such as prostate cancer [27] with either antagonists or agonists that act 
as functional antagonist.  
In 1979 a study demonstrated that radiolabeled GnRH (i.e., 125I-GnRH) associated 
rapidly to ovine anterior pituitary homogenates with a kon value of 0.78 nM-1 min-1. 
 
Figure 2. Schematic representation of biosynthesis, release and degradation kinetics 
(‘endogenous ligand kinetics’) of endogenous neuropeptides GnRH (A), NPY (B) and CRF 
(C) in the human body at physiological conditions. This cartoon describes the location of 
synthesis of the neuropeptide, followed by release, transport, and binding at its cognate 
receptor. Finally, the endogenous neuropeptide is degraded by endopeptidases. Sources of 
medical illustrations: Somersault1824 Library of Science & Medical Illustrations [22] and 
Servier medical art. [23]. 
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Dissociation of the agonist was extremely rapid, with a koff value of 0.18 min-1, translating into 
a RT of 5.6 min which was calculated from the initial slope of the dissociation curve [28].  
More recently [29], two novel competition association assays were developed that 
allowed for the first time the determination of kinetic receptor binding characteristics of a 
series of peptide agonists for the human GnRH receptor, including its endogenous ligand 
GnRH. Firstly, a novel radioligand binding competition association assay was developed in 
Box 1: Biosynthesis, release and degradation of endogenous neuropeptides  
Neuropeptides are generally synthesized from larger precursors in the neuronal cell body upon stress 
stimuli [6]. The precursors are stored in vesicles, where they are degraded by convertases into active 
peptides. Neuropeptides are transported to the release sites at neurons and released by exocytosis, 
where they bind their cognate receptor [30]. The kinetics of neuropeptide synthesis, release and 
degradation is presented in Figure 2. 
 
Gonadotropin-releasing hormone 
• GnRH is synthesized in the hypothalamus from a precursor polypeptide by enzymatic 
processing [31-33].  
• GnRH is released in pulses from the hypothalamus. GnRH secretion is regulated both by the 
feedback actions of gonadal steroids and neural input from higher cognitive and sensory 
centers [33]. The pattern of pulsatile GnRH secretion ranges from minutes to hours and varies 
between sexes, during reproductive life and during the menstrual cycle in females [24] and 
ranges in frequency between 30 min and 3-4 hours [34].  
• GnRH is rapidly hydrolyzed (half-life 2-4 min) into GnRH 1-5 by thimet oligopeptidase (EC 
3.4.24.15) both in the hypothalamus and the anterior pituitary [35-37]. 
 
Neuropeptide Y 
• NPY is synthesized in the hypothalamus and in the peripheral nervous system by sympathetic 
neurons [38] 
• NPY is released in high frequency bursts (every 5 min) from sympathetic nerve terminals, 
upon stress stimuli or pathological conditions [39, 40].  
• NPY is rapidly hydrolysed (half-life approximately 12 min) by peptidases, including dipeptidyl 
peptidase IV (EC 3.4.14.5)) and aminopeptidase P (EC 3.4.11.9) [41, 42]. 
 
Corticotropin-releasing factor and Urocortin I 
• CRF and UcnI are synthesized and released by the paraventricular nucleus of the 
hypothalamus [43].  
• The axons of hypothalamic neurons release CRF and UcnI (approximately every 5 min) into 
the hypophyseal portal blood in reaction to stress [6].  
• CRF and UcnI are rapidly hydrolyzed (half-life 12-73 min) by endothelin-converting enzyme 1 
(ECE1, EC 3.4.24.71) in the brain [44, 45]. 
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which GnRH had kon, koff and RT values of 0.06 ± 0.01 nM-1 min-1, 0.2 ± 0.02 min-1, and 6.3 ± 
0.6 min at room temperature, respectively (Table 1).  
Secondly, a homogenous time-resolved fluorescence (TR-FRET) Tag-lite™ method 
was developed as an alternative assay for the same purpose. These TR-FRET experiments 
provided similar kon, koff and RT values for GnRH of 0.02 ± 0.01 nM-1min-1, 0.44 ± 0.3 min-1, 
and 2.3 ± 1.6 min at room temperature, respectively [29]  (Table 1).  
 
Table 1. Qualitative overview of the kinetic profile, i.e. the release kinetics of the endogenous 
ligand(s), binding kinetics and receptor internalization rates, of the GnRH receptor, NPY receptors 
and CRF1 receptor (see also Box 1). 
Neuropeptide system Fast* Medium* Slow* 
GnRH 
Release kinetics** GnRH X   X 
Binding kinetics GnRH-GnRHR X   
Internalization kinetics GnRHR   X 
NPY 
Release kinetics*** NPY X   
Binding kinetics 
NPY-Y1R kon koff  
NPY-Y2R kon  koff 
NPY-Y5R kon koff  
Internalization kinetics 
Y1R X   
Y2R   X 
Y5R   X 
CRF 
Release kinetics*** 
CRF X   
UCNI X  X 
Binding kinetics 
CRF-CRF1R kon  koff 
UCNI-CRF1R  X  
Internalization kinetics CRF1R males  females 
* Fast, medium and slow kinetics are an arbitrary categorization in proportion to the target system, 
exact rates can be found in the corresponding paragraph.  
** GnRH release is pulsatile ranging from minutes to hours and depends on gender, age and 
menstrual cycle, see also Box 1. 
*** NPY, CRF and UCNI are released in high frequency bursts in response to stress or pathological 
conditions, see also Box 1. 
 
The lack of an intracellular C-terminal tail on the GnRH receptor results in the 
absence of rapid arrestin-mediated desensitization and in very slow internalization rates [26, 
46]. Madziva et al. showed less than 50% internalization after 60 min stimulation with a 
GnRH analogue [47]. Additionally, Pawson et al. showed that mammalian GnRHRs (human 
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and rat) undergo slow, constitutive (i.e. agonist-independent) internalization [46]. The 
importance of a C-terminal tail for receptor internalization was shown by two studies; firstly, 
the catfish GnRH receptor that does possess an intracellular C-terminal tail displayed rapid 
desensitization and internalization. It was shown that approximately 50% of the catfish GnRH 
receptors were internalized after 15 min stimulation with chicken II GnRH (endocytosis rate 
constant = 0.099 min-1) [48]. Secondly, addition of a functional intracellular C-terminal tail of 
the thyrotropin-releasing hormone receptor (TRHR) to the rat GnRHR produced rapid 
desensitization and increased receptor internalization rates [48].  
In brief, drugs targeting the GnRHR are competing with fast association and 
dissociation kinetics of endogenous GnRH that is released in pulses ranging from minutes to 
hours reaching plasma concentrations up to 1.7 µM. In particular, high frequency GnRH 
bursts should be considered when designing drugs competing with GnRH. In addition, the 
GnRHR internalizes slowly and is thus not a limiting factor for drugs to be effective. We 
hypothesize that (functional) antagonists targeting the GnRH receptor should have a long 
residence time to overcome the high frequency pulses and fast association kinetics of the 
endogenous ligand. This is particularly beneficial when chronic treatment is desired, e.g. for 
treatment of prostate cancer or endometriosis.  
 
Box 2: Alternative mechanisms involved in regulating ligand concentrations 
Neuropeptides are generally degraded by peptidases, and reuptake systems or binding 
proteins are often not involved in regulating free ligand concentrations. However, a few exceptions 
have been reported where alternative mechanisms are proposed to regulate high neuropeptide 
concentrations.  
For instance, a binding protein has been discovered, called the CRF binding protein (CRF-
BP), that binds CRF, Ucn1 and their associated peptides with high affinity [49]. This protein is broadly 
distributed throughout the brain and its  predominant role is to bind and clear CRF from the blood. 
CRF-BP is also expressed in the liver and placenta where it is believed to modulate CRF levels and 
protect the body from increased plasma CRF levels, particularly during late stages of pregnancy [50].  
Another exception is reported for cholecystokinin octapeptide (CCK8). The degradation of 
CCK8 by peptidases is much slower in comparison to other neuropeptides and therefore an alternative 
control mechanism was hypothesized. A highly selective uptake mechanism was reported that 
together with peptidases enables termination of CCK8 activity [51].  
 Taken together, ligand-binding proteins and reuptake systems, although rare, can play a role 
in regulating free neuropeptide concentrations and should therefore be considered regarding 
endogenous neuropeptide concentrations. 
 
Neuropeptide Y and Neuropeptide Y receptors 
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Neuropeptide Y (NPY) is a 36 amino acid neuropeptide hormone that acts as a 
neurotransmitter in the central nervous system (CNS). NPY is the principal endogenous 
agonist at neuropeptide Y type 1 (Y1), type 2 (Y2) and type 5 (Y5) receptors. NPY is released 
in high frequency bursts upon stress stimuli (Box 1 and Figure 2) [39] and plasma 
concentrations are reported to be around 10 µM [52]. NPY receptors belong to class A 
GPCRs and are coupled to Gi or Go proteins [53]. NPY receptors and their endogenous 
ligands are involved in the control of appetite, inhibition of anxiety in the CNS, presynaptic 
inhibition of neurotransmitter release in the CNS and periphery, the modulation of circadian 
rhythm and pain transmission [54]. NPY receptors are mainly targeted to treat stress-related 
disorders but also in pain treatment, cancer and epilepsy [2].  
 The kinetic binding profile of endogenous neuropeptide Y ligands to human Y1, Y2, 
and mouse Y5 receptors was extensively studied by Dautzenberg et al. At 22°C, 125I-NPY 
displays rapid association to hY1, hY2 and mY5 receptors (Table 1). Dissociation of 125I-NPY 
from the mY5 receptor and hY1 receptor provided residence times between 50 and 80 min. In 
contrast, minimal dissociation (approximately 20%) of 125I-NPY from both recombinant and 
endogenous Y2 receptor was observed after 24 h incubation. These findings indicate a 
pseudo-irreversible binding mode of NPY to the hY2 receptor [55], which adds complexity to 
drug development targeting the hY2 receptor.  
 Receptor internalization rates, as well as subsequent degradation or resensitization 
differ substantially between the different NPY receptor subtypes. Upon human NPY 
exposure, the Y1 receptor is rapidly internalized via clathrin-dependent endocytosis [56-58]. 
In addition, resensitization studies demonstrated that the Y1 receptor is rapidly recycled back 
to the cell membrane [56, 58, 59]. In contrast, Y2 receptors neither internalize nor desensitize 
[56], or only to a small extent with extremely slow internalization rates after prolonged agonist 
exposure [57, 60]. Internalization of Y5 receptors has not been extensively studied yet. 
However, it was reported that this receptor internalizes to a much slower extent than Y1 [60-
62]. 
 In conclusion, target kinetics for the NPY receptor subtypes vary greatly and NPY is 
released in high frequency bursts upon stress stimuli with plasma concentrations around 10 
µM. Rapid association and dissociation kinetics as well as internalization rates were 
observed for the NPY-hY1 receptor complex. In contrast, while the binding kinetics of NPY to 
the hY2 receptor are similar to the hY1 receptor, internalization of hY2 is extremely slow. hY5 
internalization has also been reported to be slow, with fast association and slow dissociation 
rates of NPY. Therefore, we postulate that drugs with fast binding kinetics are desirable 
when targeting the hY1 receptor, while fast association and slow dissociation kinetics are 
beneficial for hY2 and hY5 receptors. Slowly dissociating agonists are particularly interesting 
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for cancer treatment as they might accelerate receptor internalization [63] while a slowly 
dissociating antagonist could be beneficial for the treatment of obesity [64].   
 
CRF, UcnI and the CRF1R 
Corticotropin releasing factor (CRF) and urocortin 1 (UcnI) are hormones that are the 
primary CNS neuromodulators of the hypothalamic-pituitary-adrenal axis. CRF and UcnI 
regulate adrenocorticotropic hormone (ACTH) secretion by the pituitary and are critical 
neurotransmitters in the neuroendocrine and behavioral response to stress [67]. CRF and 
UcnI are released in high frequency bursts in response to stress (Box 1 and Figure 2) [6]. 
UcnI is mainly expressed in cell bodies of the Edinger Westphal nucleus in the brain while 
CRF is more widely expressed in the CNS [68]. Plasma concentrations of UcnI are reported 
to reach up to 5 µM, while maximal 
CRF concentrations are much lower 
(around 2 pM). During stress and/or 
pathological conditions levels of both 
endogenous ligands increase, which 
is most noticeable for CRF of which 
levels can go up to 0.5 mM [69-71].  
CRF and UcnI exert their effect by 
activation of two CRF receptor 
subtypes, CRF1 and CRF2 receptors. 
These receptors both belong to the 
secretin-like class B subfamily of 
GPCRs and are primarily coupled to 
Gs proteins. Several studies have 
indicated the involvement of the CRF 
system in human stress disorders, 
such as anxiety, depression and 
addiction [72]. 
Ligand binding kinetics 
studies of CRF and UcnI to the CRF1 
receptor are limited (Table 1). In an 
early study De Souza et al., studied the binding of 125I-[Tyr0] CRF (125I-rCRF) to rat olfactory 
membranes at different temperatures [73]. This study demonstrated temperature-dependent 
125I-rCRF association to rat CRF1 receptors with a kon value of 0.52 nM-1 min-1 at 23°C. At this 
temperature, dissociation was reversible and monophasic, with a koff value of 0.007 min-1 and 
Box 3: Examples of drugs targeting neuropeptide 
GPCRs with optimized binding kinetics.  
As this was all studied in retrospect, these examples 
demonstrate the need for a better understanding of the 
kinetic profile of the target receptor and its endogenous 
ligands, in addition to the drug candidate.  
 
Candesartan is a marketed angiotensin II subtype-1 (AT1) 
receptor antagonists for the treatment of hypertension. It 
has a residence time of 173 min (37°C) [11].   
Aprepitant and netupitant are marketed NK1R 
antagonists to treat chemotherapy-induced emesis. 
Aprepitant has a residence time of 154 min (22°C) [11] 
and netupitant has been reported as an insurmountable 
antagonist with antagonistic effects lasting over 5 hours 
[65].  
Suvorexant is a dual orexin receptor antagonist to treat  
insomnia. It has a residence time of 83 min for the orexin 
type 2 (OX2) receptor (room temperature) [66]. 
Buserelin is a GnRH peptide agonist used to treat 
hormone dependent diseases. It has a reported residence 
time of 111 min at 25 °C [29]. 
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RT of 143 min while association and dissociation were more rapid at physiological 
temperature [73]. In contrast, [3H]-UcnI association to the human CRF1 receptor was slow 
and monophasic with a kon value of 0.06 ± 0.024 nM-1 min-1 while dissociation was faster in 
comparison to CRF with a reported koff value of 0.017 ± 0.007 min-1 and RT of 58 min at room 
temperature [74].  
CRF1 receptors undergo rapid desensitization and internalization during continuous 
exposure to CRF or UcnI [75]. Although UcnI- and CRF-induced CRF1 receptor 
internalization occurred to a similar degree, the receptor was shown to recycle and 
resensitize more efficiently after CRF stimulation [44]. Moreover, there is evidence of sex 
differences in CRF1 receptor signaling and trafficking [76]. In male rats, a swim stress 
paradigm promoted CRF1 receptor β-arrestin2 association, and internalization in LC neurons. 
However, in female rats stress-induced CRF1 receptor-β-arrestin 2 association remained low, 
and stress-induced CRF1 receptor internalization was impaired [76]. Valentino et al. 
suggested that sex biases in both CRF1 receptor coupling to G proteins, and CRF1-β-arrestin 
2 association makes females more sensitive to acute stress and less able to adapt to chronic 
stress [77].  
To summarize, although ligand binding kinetics studies on the CRF1 receptor are 
limited, it is likely that drugs targeting the CRF1 receptor are competing with fast binding 
kinetics of CRF but slower binding kinetics of UcnI. Additionally, CRF1 receptor 
desensitization and internalization is fast in males but slow in females. These gender-specific 
internalization kinetics should be taken into account in the design of novel agonistic drugs 
targeting the CRF1 receptor when treating e.g. depression. Antagonists targeting the CRF1 
receptor to treat e.g. addiction should have fast association and slow dissociation rates to 
overcome the slow dissociation kinetics of CRF and high plasma concentrations of both CRF 
and UCNI during stress. Considering that stress-related disorders often need chronic 
treatment, patients could benefit from slowly dissociating drugs.   
Concluding remarks 
Drug-target association and dissociation rates play an important role in achieving safe 
and efficacious drug action in vivo. For example, numerous drugs have been proven in 
retrospect to be highly efficacious due to their slow dissociation rates (Box 3). Currently, drug 
discovery efforts are moving towards incorporating optimized binding kinetics prospectively. 
As many successful drugs on the market achieve their effects by competing with 
endogenous ligands, a better understanding of the pharmacological and physiological 
behavior of endogenous ligands and their receptors in the human body is crucial. This is 
particularly important for neuropeptides, since their release is generally pulsatile or in bursts 
consequent to stress stimuli, ultimately resulting in instant high local concentrations. 
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Moreover, to understand desired binding kinetics for the target of interest, insights into 
receptor internalization kinetics are beneficial, as this arguably terminates a drug’s effect.  
In this review we have presented evidence of varying ligand binding kinetics for the 
endogenous ligands of three exemplary neuropeptide receptors. In addition to the observed 
variability in ligand binding kinetics across these three exemplars, receptor internalization 
kinetics were also largely different for all three discussed neuropeptide receptors. Thus, 
collectively, this small case overview demonstrates a broad array of kinetic profiles for 
neuropeptide receptors, i.e. endogenous ligand release rates, binding kinetics and receptor 
internalization rates. Presently, drug discovery focusses mainly on characterizing drug 
candidates only, while the kinetic profile of the target receptor and its endogenous ligand(s) 
are most often neglected. Therefore, we believe it is a great opportunity for future drug 
research to include the kinetic profile of the target receptor and its endogenous ligand(s) to 
the drug discovery paradigm. Knowledge of these complete kinetic profiles could improve our 
understanding of desired binding kinetics and in turn lead to less attrition in (pre-) clinical 
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Drug-target residence time is an important, yet often overlooked, parameter in drug 
discovery. Multiple studies have proposed an increased residence time to be beneficial for 
improved drug efficacy and/or longer duration of action.  
Currently there are many drugs on the market targeting the gonadotropin-releasing 
hormone (GnRH) receptor for the treatment of hormone-dependent diseases. Surprisingly, 
the kinetic receptor binding parameters of these analogues have not yet been reported. 
Therefore, this project focused on determining the receptor binding kinetics of twelve GnRH 
peptide agonists, including many marketed drugs. 
We successfully developed and optimized a novel radioligand binding competition 
association assay for the human GnRH receptor with the use of a radiolabeled peptide 
agonist, 125I-triptorelin. In addition to radioligand binding studies, a homogenous time-
resolved fluorescence (TR-FRET) Tag-lite™ method was developed as an alternative assay 
for the same purpose. Both assays were applied to determine the kinetic receptor binding 
characteristics of twelve high affinity GnRH peptide agonists. Results obtained from both 
methods were highly correlated. Interestingly, the binding kinetics of the peptide agonists 
were more divergent than their affinities with residence times ranging from 5.6 min 
(goserelin) to 125 min (deslorelin).   
Our research provides new insights by incorporating kinetic, next to equilibrium, 
binding parameters in current research and development that can potentially improve future 





Drug target residence time is emerging as an important parameter in the drug 
discovery process. Multiple studies provide evidence that the binding kinetics of drug target 
interactions rather than the typical equilibrium binding parameters are important for in vivo 
efficacy [1-4]. Several marketed drugs in the field of G protein-coupled receptors (GPCRs) 
have retrospectively been shown to display slow receptor dissociation rates, or, in other 
words, long receptor residence times [5]. For instance, the histamine H1 receptor antagonist 
desloratidine was found to have a long residence time, which could explain its high potency 
and 24 hours duration of action observed in clinical studies [6]. Another example is the 
insurmountable antagonist for the angiotensin II subtype-1 (AT1) receptor, telmisartan. The 
authors deemed the insurmountability and therefore improved efficacy of telmisartan to be 
partly due to its very slow dissociation from AT1 receptors [7].  
The hypothalamic neuropeptide gonadotropin-releasing hormone (GnRH) is a central 
mediator of reproductive functions. This decapeptide binds to a class A GPCR, namely the 
GnRH receptor (GnRHR) located mainly on pituitary gonadotrophs. Along with the pituitary, 
GnRH receptors are expressed in reproductive tissues, both normal and malignant, such as 
those of the prostate and mammary gland [8-11]. Upon receptor activation, the 
gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH) are 
synthesized and secreted from gonadotrophic cells. LH and FSH consecutively induce follicle 
stimulation and ovulation in females and promote steroidogenesis in both males and females 
[12].  
The pulsatile release of GnRH from the hypothalamus is essential for the 
maintenance of ovarian function. Sustained exposure of GnRHR to GnRH or GnRH 
analogues leads to activation, commonly named ‘’flare’’, followed by desensitization of 
GnRHR-mediated gonadotropin secretion. Accordingly, blockade by antagonists or 
desensitization of GnRHR-mediated gonadotropin secretion both ultimately reduce 
circulating levels of gonadotropins and gonadal steroids [13, 14]. This so called chemical 
castration underlies the therapeutic use of GnRH analogues to treat sex hormone-dependent 
diseases [15-17].  
Consequently, considerable efforts have been put towards the development of 
agonists and antagonists targeting the GnRH receptor [18-22]. Only a few studies have 
examined the receptor binding kinetics of GnRH ligands. A paper of Heise et al. [23] 
described a scintillation proximity assay to qualitatively distinguish between fast and slowly 
dissociating antagonists for the GnRH receptor. The authors demonstrated that slow 
dissociation rates were responsible for large discrepancies between a ligand’s Ki value 
determined at 30 minutes versus 10 hours and they suggested using the Ki ratio as a 
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screening method to select slowly dissociating compounds. Two other studies focused on a 
quantitative determination of receptor binding kinetics of small molecule GnRH antagonists. 
Here, a direct correlation between the insurmountability and slow dissociation rates of these 
antagonists was shown [24, 25].    
Currently multiple peptide GnRH analogues have been approved for the treatment of 
advanced prostatic cancer, endometriosis, in vitro fertilization and more [15-17, 26-29]. 
Remarkably, the receptor binding kinetics of peptide GnRH receptor ligands have never been 
reported. Therefore, we developed a novel radioligand binding competition association assay 
that allowed us to determine the kinetic binding parameters and focused on twelve GnRH 
peptide agonists, including many marketed drugs (Table 1). In addition, we compared these 
kinetic parameters with those from a newly developed homogenous time-resolved 
fluorescent (HTRF) assay. Both assays may improve future drug discovery targeting the 
GnRH receptor by incorporating kinetic receptor binding parameters into current research 
and development trajectories. 
 
Material & methods 
Reagents and peptides 
 Deslorelin and fertirelin (Table 1) were obtained from Genway Biotech Inc. (San 
Diego, CA, U.S.A.) and American Peptide Company (Sunnyvale, CA), respectively. All other 
peptide analogs (Table 1) and bovine serum albumin (BSA) were purchased from Sigma-
Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). BCA (bicinchoninic acid) protein assay 
reagent was obtained from Pierce Chemical Company (Rockford, IL, U.S.A.).  125I-triptorelin 
(specific activity 2200 Ci/mmol) was purchased from PerkinElmer (Groningen, The 
Netherlands). Chinese Hamster Ovary cells stably expressing the human gonadotropin-
releasing hormone receptor (from now on CHOhGnRH cells) were kindly provided by MSD 
(Oss, The Netherlands). Tag-lite™ HEK293 cells containing a stably overexpressed human 
GnRH receptor labeled with Tb (from now on Tag-lite™ GnRH cells) were obtained as frozen 
stocks from Cisbio (Codolet, France). A buserelin-derived tracer, labeled at the 6th position 
with a red emitting fluorophore and Tag-lite™-buffer (TLB) were also purchased from Cisbio 
(Codolet, France). All other chemicals and cell culture materials were obtained from standard 
commercial sources. The molecular target nomenclature (GnRHR) conforms to ‘The Concise 





 For radioligand binding assays, CHOhGnRH cells were grown in Ham’s F12/DMEM 
(1:1) medium supplemented with 10% normal bovine serum, 2 mM glutamine, penicillin (100 
IU/mL), streptomycin (100 µg mL-1) and G418 (200 µg mL-1) at 37 °C in 5% CO2.  
For TR-FRET experiments, 1 ml (7 *106 cells ml-1) of Tag-lite™ GnRH cells were 
thawed, washed with 15 ml ice-cold TLB, resuspended in 5 ml TLB and immediately used. 
  
Membrane Preparation  
CHOhGnRH cells were scraped from the plates in 5 mL PBS, collected and 
centrifuged at 700 g (3000 rpm) for 5 min. Derived pellets were pooled and resuspended in 
50 mM Tris HCl buffer pH 7.4 at 25 °C supplemented with 2 mM MgCl2, and subsequently 
homogenized with an UltraThurrax (Heidolph Instruments, Germany). The cytosolic fraction 
and membranes were separated by centrifugation at 100 000 g (31 000 rpm) in an Optima 
LE-80K ultracentrifuge (Beckman Coulter, Fullterton, CA, U.S.A.) for 20 min. at 4 °C. The 
pellet was resuspended and centrifugation was repeated. The obtained pellet was 
resuspended, membranes were aliquoted and stored at -80 °C. Membrane protein 
concentrations were determined using the BCA method with BSA as a standard [31].  
Table 1: Amino acid sequences of the twelve examined GnRH peptide agonists. The differences 
between the peptides are expressed in bold.  
                 1 2 3 4 5 6 7 8 9 10 
GnRH pGlu* His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2 
Triptorelin pGlu* His Trp Ser Tyr D-Trp Leu Arg Pro Gly-NH2 
[D-Ala6]-
GnRH 
pGlu* His Trp Ser Tyr D-Ala Leu Arg Pro Gly-NH2 
[D-Lys6]-
GnRH 
pGlu* His Trp Ser Tyr D-Lys Leu Arg Pro Gly-NH2 
Fertirelin pGlu* His Trp Ser Tyr Gly Leu Arg Pro NHEt* 
Alarelin pGlu* His Trp Ser Tyr D-Ala Leu Arg Pro NHEt* 
Deslorelin pGlu* His Trp Ser Tyr D-Trp Leu Arg Pro NHEt* 
Leuprorelin pGlu* His Trp Ser Tyr D-Leu Leu Arg Pro NHEt* 
Nafarelin pGlu* His Trp Ser Tyr D2Nal Leu Arg Pro Gly-NH2 
Buserelin pGlu* His Trp Ser Tyr Ser-tBu* Leu Arg Pro NHEt* 
Goserelin pGlu* His Trp Ser Tyr Ser-tBu* Leu Arg Pro aGly-NH2* 
Histerelin pGlu* His Trp Ser Tyr His(Bzl)* Leu Arg Pro NHEt* 
*pGlu = pyroglutamic acid, D2Nal = (2-naphthyl)-D-alanine, Ser-tBu = serine-tert-butyl, His(Bzl) = N-
benzyl-L-histidine, aGly-NH2 = aza-glycine amine, NHEt = ethylamide 
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Radioligand Equilibrium Assays 
 Displacement experiments were performed as previously reported [32]. In short, 
membrane aliquots containing 15-20 µg protein were incubated in a total volume of 100 µL 
assay buffer (25 mM Tris HCl, pH 7.4 at 25 °C, supplemented with 2 mM MgCl2, 0.1 % (w/v) 
BSA) at 25 °C for 2 hours. Ten concentrations of competing ligand were used in the 
presence of 30.000 cpm (~0.1 nM) 125I-triptorelin. At this concentration, total radioligand 
binding did not exceed 10% of that added to prevent ligand depletion. Non-specific binding 
was determined in the presence of an excess amount of GnRH (1 µM). The reaction was 
terminated by the addition of 1 mL ice-cold wash buffer (25 mM Tris HCl, pH 7.4 at 25 °C, 
supplemented with 2 mM MgCl2 and 0.05% (w/v) BSA). Separation of bound from free 
radioligand was performed by rapid filtration through Whatman GF/B filters saturated with 
0.25% polyethylene imine (PEI) using a Brandel harvester. Filters were subsequently 
washed three times with 2 mL ice-cold wash buffer. Filter bound radioactivity was determined 
using a γ-counter (Wizard 1470, PerkinElmer).  
 
Radioligand Kinetic Association and Dissociation Assays 
 Association experiments were carried out by incubating membrane aliquots 
containing 15-20 µg protein in a total volume of 100 µL assay buffer at 25 °C with 30.000 
cpm (~0.1 nM) 125I-triptorelin. The amount of radioligand bound to the receptor was 
determined at different time intervals for a total incubation time of 120 min.  
 Dissociation experiments were performed by preincubating membrane aliquots 
containing 15-20 µg protein in a total volume of 100 µL assay buffer at 25 °C for 45 min with 
30.000 cpm (~0.1 nM) 125I-triptorelin. After preincubation, dissociation was initiated by 
addition of an excess amount of GnRH (1 µM) in a total volume of 2.5 µL. The amount of 
radioligand still bound to the receptor was measured at various time intervals for a total 
incubation time of 120 min. The reaction was stopped and samples were harvested as 
described under Radioligand Equilibrium Assays.  
 
Radioligand Kinetic Competition Association Assays 
 The binding kinetics of unlabeled ligands were quantified using the competition 
association assay based on the method by Motulsky and Mahan [33]. During optimization, 
three different concentrations of unlabeled triptorelin were tested; 0.3-, 1- and 3-fold its Ki 
value. The kinetic parameters of all other unlabeled ligands were determined at a 
concentration of 1-fold their Ki, unless stated otherwise. The competition association assay 
was initiated by adding membrane aliquots containing 15-20 µg protein in a total volume of 
100 µL assay buffer at 25 °C with 50.000 cpm (~0.15 nM) 125I-triptorelin in the absence or 
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presence of competing ligand. Of note, total radioligand binding did not exceed 10% of that 
added at this concentration to prevent ligand depletion. The amount of radioligand bound to 
the receptor was determined at different time intervals for a total incubation time of 120 min.  
The reaction was stopped and samples were harvested as described under Radioligand 
Equilibrium Assays. 
 
TR-FRET Probe Equilibrium Assays 
Unless otherwise specified, TR-FRET measurements were carried out using the 
conditions described in [34]. To determine the equilibrium affinity of the fluorescent probe, 5 
µl Tag-lite™ GnRH cells (1400 cells µl-1) were incubated for 1 h, to ensure signal stability, 
with increasing probe concentrations (ranging from 0 to 100 nM: Supplementary Figure S1) 
in a final volume of 10 µl. In parallel, a non-specific binding control was carried out in the 
presence of an excess amount of buserelin (100 µM). Binding signals were measured in a 
PHERAstar FS plate reader by exciting the Tb donor with 5 laser flashes at a wavelength of 
337 nm and recording acceptor and donor emission fluorescence channels (A and B 
channels), at wavelengths of 520 nm and 490 nm respectively. 
 
TR-FRET Equilibrium Probe Competition Assays 
“Ready-to-use” assay plates containing serial dilutions of the test agonists were 
prepared as described in [34]. Subsequently 5 µl Tag-lite™ GnRH cells (1400 cells µl-1) and 
50 nM probe were added to the competitors and incubated at room temperature for 1 h, to 
ensure signal stability, in a final volume of 10 µl. Non-specific binding (“low signal”) controls 
contained an excess amount of buserelin (100 µM), whereas in “high signal” controls, the test 
compounds were replaced by DMSO. Binding signals were recorded as described under TR-
FRET Probe Equilibrium Assays. 
 
TR-FRET Kinetic Probe Association and Dissociation Assays 
Measurements were carried out in quadruplicate and in a final volume of 15 µl well-1. 
First, a 5-point, 2-fold serial dilution of fluorescent probe (Supplementary Figure 2) was pre-
dispensed on black 384 well low volume plates (Greiner) and the the PHERAstar FS injection 
system’s syringes (previously washed with NaOH/H2O) were either primed with 1500 µl 
solution of Tag-lite™ GnRH cells, (1000 cells µl-1)  or with 200 µM buserelin. Then, 4 µl of 
cells were quickly added to the probe with the first syringe and the association traces were 
recorded as described under TR-FRET Probe Equilibrium Assays, with kinetic intervals of 26 
seconds. After 30 min, fluorescent probe dissociation was initiated by addition of 5 µl of an 
excess of unlabeled buserelin (final concentration 67 µM) with the second syringe and the 
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traces were recorded with kinetic intervals of 300 seconds in the same fashion. Alternatively 
a 1-point measurement was performed with 5 µL of probe (final concentration 25 nM) and 5 
µL of Tag-lite™ GnRH cells (1400 cells/µL) and association was recorded with kinetic 
intervals of 120 seconds. After 24 min dissociation was initiated and recorded with the same 
kinetic interval. 
 
TR-FRET Kinetic Probe Titration Assays 
First, 5 µL of increasing concentrations of fluorescent probe was dispensed into 384 
well plates, the injection system of the PHERAstar FS plate reader was primed with Tag-
lite™ GnRH cells as described under TR-FRET Probe Equilibrium Assays. Then, 5 µl of cell 
solution was added with the syringe and the TR-FRET signals corresponding to probe 
association were recorded as described under TR-FRET Probe Equilibrium Assays. 
 
TR-FRET Kinetic Probe Competition Assays (kPCA) 
 The basic principle of this assay is explained in  [34]. Prior to each experiment, 6 µL 
of fluorescent probe (final concentration 15 nM) was dispensed to the “assay-ready” plates 
containing 100 nl of compound dilutions using a Multidrop Combi and the injection system of 
the PHERAstar FS plate reader was washed with NaOH/H20 and primed with Tag-lite™ 
GnRH cells. Finally, the assay plates were introduced into the instrument, 4 µl of cells (1000 
cells/μl) were rapidly dispensed with the syringe to each well and the TR-FRET signals 
corresponding to the competitive binding of probe and test compounds were recorded as 
described under TR-FRET Probe Equilibrium Assays with kinetic intervals of 78 seconds.  
 
Data Analysis  
All experimental data were analyzed using the nonlinear regression curve-fitting 
program GraphPad Prism v. 5.00 (GraphPad Software Inc., San Diego, CA). Further details 
on the handling of TR-FRET data are available in [34]. 
For radioligand binding assays, the previously reported KD value of 0.35 nM for 125I-triptorelin 
[32] was used to convert IC50 values obtained from competition curve analysis into Ki values 
with the help of the Cheng-Prusoff equation [35]: 
       
Ki = IC50/(1+[radioligand]/KD) 
 
Likewise, a KD value of 0.8 nM obtained for the “red”-labeled buserelin by fitting the 
data from the TR-FRET Probe Equilibrium Binding Assay (Supplementary Figure S1) to the 
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model “One site – Specific binding”, was used to convert IC50 values from TR-FRET 
experiments to Ki values. 
 
The observed association rates (kobs) derived from both assays were obtained by 
fitting association data using one phase exponential association. The dissociation rates were 
obtained by fitting dissociation data to a one phase exponential decay model. The kobs values 
were converted into association rate (kon) values using the following equation: 
    
kon = (kobs – koff)/[radioligand] 
 
The association and dissociation rates were used to calculate the kinetic KD using the 
following equation: 
   
KD = koff/kon 
 
To further validate probe affinity and kinetic rate constants, association data from 
kinetic probe titration experiments were fitted to the ‘’Association kinetics – two or more 
concentrations of hot’’ model (Supplementary Figure S2). The obtained kon from these 
experiments and KD from equilibrium binding was used to calculate koff as described above.  
 
Association and dissociation rates for unlabeled ligands were calculated by fitting the 











































































Where k1 is the kon of the radioligand (M-1min-1), k2 is the koff  of the radioligand (min-1), 
L is the radioligand concentration (nM), I is the concentration of the unlabeled competitor 
(nM), X is the time (min) and Y is the specific binding of the radioligand (DPM). During a 
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competition association these parameters are set, obtaining k1 from the control curve without 
competitor and k2 from previously performed dissociation assays described under 
Radioligand Association and Dissociation Assays. With that the k3, k4 and Bmax can be 
calculated, where k3 represents the kon (M-1min-1) of the unlabeled ligand, k4 stands for the koff 
of the unlabeled ligand and Bmax equals the total binding (DPM). All competition association 
data were globally fitted.  
In case of kPCA, the kinetics of the competitive binding model was enhanced with a 
mathematical term describing a mono-exponential decay that accounts for signal drift [34]. 
As stated for the radioligand binding assays, the kinetic rate constants of the fluorescent 
probe (k1 and k2) were determined in separate experiments and set constant in kPCA data 
analysis. 
 
The residence time (RT) was calculated as in the following equation: 
 




All values obtained from radioligand binding 
assays are means of at least three 
independent experiments performed in 
duplicate, unless stated otherwise. Values 
obtained from TR-FRET assays are means 
of two independent experiments performed 
in quadruplicate, unless stated otherwise.     
 
Results 
Determination of the association and 
dissociation rate constants of 125I-
triptorelin 
The binding properties of 125I-
triptorelin to CHOhGnRH membranes were 
quantified with traditional kinetic radioligand 
binding assays. Association and 
dissociation experiments provided kon and 
koff values of 0.4 ± 0.1 nM-1min-1 and 0.05 ± 
0.0004 min-1, respectively (Figure 1A and 
Table 2). From these data the equilibrium 
dissociation constant (kinetic KD) was 
calculated, which had a value of 0.2 nM. 
 
Determination of the association and 
dissociation rate constants of the 
fluorescently labeled buserelin 
derivative probe 
A fluorescently labeled buserelin 
derivative was used as a probe in all TR-
FRET assays. The kinetic parameters of the 
fluorescent tracer were determined by 
performing association and dissociation 
experiments. Experiments yielded a kon and koff of 0.008 ± 0.001 nM-1min-1 and 0.01 ± 0.001 
min-1, respectively (Figure 1B, Table 3, Supplementary Figure 2). The kinetic KD value 
calculated from these experiments was 1.2 nM. 
 
Figure 1: Association and dissociation 
kinetics of 125I-triptorelin (A and B, 
respectively) or fluorescent probe (C) at the 
hGnRH receptor. Representative graphs from 
one experiment performed in duplicate (see 





Determination of the binding affinity of hGnRHR agonists with 125I-triptorelin 
Equilibrium radioligand binding assays were performed to assess the ability of twelve 
GnRH analogues to displace 125I-triptorelin from CHOhGnRH cell membranes. All ligands 
were able to fully displace 125I-triptorelin in a concentration-dependent manner (Figure 2A 
and Table 4). All peptides had a Hill-coefficient close to unity in the 125I-triptorelin 
displacement assay (data not shown), which indicated a competitive mode of inhibition with 
regard to the radioligand. Of all tested ligands nafarelin had the highest affinity for the 
Table 2: Comparison of the affinity, dissociation constants and kinetic parameters of 
reference agonist triptorelin obtained with different radioligand binding assays 
Assay pKDb and (KD 
(nM)) 





Displacement N.A. 9.6 ± 0.09 (0.27) N.A. N.A. 
Association and 
dissociation 




9.7 ± 0.12 (0.22) N.A. 0.12 ± 0.014 0.026 ± 0.008 
Values are means ± SEM of three separate experiments performed in duplicate. N.A., not 
applicable. aThe binding kinetics of unlabeled triptorelin were determined by addition of 0.3-, 
1- and 3-fold its Ki value. bKD = koff/kon 
Table 3: Comparison of the affinity, dissociation constants and kinetic parameters of the 
fluorescent buserelin probe obtained with different TR-FRET assays 







9.1 ± 0.8 (0.8) N.A. N.A. N.A. 
Association and 
dissociationa 





8.7 ± 0.06 (2.1) N.A. 0.008 ± 0.001 0.016 ± 
0.002 
Values are means ± SEM of three separate experiments. N.A., not applicable. aThe 
dissociation kinetics of fluorescently labeled buserelin derivative were determined by 
addition of 10 µM buserelin. b koff = KD(equilibrium)/kon 
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hGnRH receptor with a Ki value 
of 0.06 nM and GnRH had the 
lowest affinity of 13 nM. All other 
ligands had affinities in the low 
to sub-nanomolar range. 
 
Determination of the binding 
affinity of hGnRHR agonists 
with TR-FRET 
The binding affinity of 
twelve agonists was also 
determined using a fluorescently 
labeled buserelin derivative as a 
tracer and Tag-lite™ GnRH cells 
in a TR-FRET assay. In 
accordance with the radioligand 
binding results, all agonists were 
able to fully displace the 
fluorescent tracer from the 
hGnRH receptor in a 
concentration-dependent 
manner (Figure 2B and Table 4). 
The data were in fair agreement 
with the affinities determined in the radioligand displacement assay despite the inherent 
differences between the two assays (r2=0.5 and p<0.05) (Figure 4C). 
Validation and optimization of the competition association assay with 125I-triptorelin 
With the kon and koff values of 125I-triptorelin obtained from traditional association and 
dissociation experiments, the kon (k3) and koff (k4) values of unlabeled triptorelin could be 
determined by fitting the kinetic parameters into the model of ‘kinetics of competitive binding’ 
as described under ‘Material & Methods’.  Three different concentrations of unlabeled 
triptorelin were tested and presented a shared kon (k3) and koff (k4) value of 0.1 ± 0.01 nM-
1min-1 and 0.03 ± 0.008 min-1, respectively (Figure 3A). These values were in good 
agreement with the association and dissociation rates obtained with traditional kinetic 
experiments (Table 2). Additionally, a comparison of the affinity (0.3 nM) and dissociation  
 
Figure 2: Displacement of 125I-triptorelin (A) or 
fluorescent probe (B) from the hGnRH receptor by the 
twelve peptide agonists.  Representative graphs from 




constants (0.1 nM and 0.2 nM), 
acquired from equilibrium and kinetic 
experiments respectively, further 
confirmed the competition association 
assay as a valid tool to determine the 
binding kinetics of unlabeled ligands at the 
hGnRH receptor (Table 2).  
 
To improve the throughput of this 
assay, one concentration of competitor 
was selected that yielded an assay 
window discernable from both the baseline 
and control curve (i.e. specific binding 
approximately 40-60%). In this case, a 
concentration of competitor equal to 1-fold 
its Ki value presented the best assay 
window. Analysis of this single 
concentration showed similar kinetic rates 
for triptorelin in comparison to the three-
concentration method, which were 
statistically indifferent (data not shown; 
p>0.05). Thus, this one-concentration 
method was used for subsequent 
determination of the binding kinetics of other unlabeled hGnRHR peptide agonists.  
 
Determination of the receptor binding kinetics of unlabeled hGnRHR agonists with 
125I-triptorelin  
By use of the one-concentration competition association assay the binding kinetics of 
11 other unlabeled hGnRHR agonists were quantified (Figure 3B, Table 5). Juxtaposing 
affinities (Ki values) and dissociation constants (KD values) acquired from equilibrium and 
kinetic experiments resulted in a high correlation (r2 = 0.9, p<0.0001). Firstly, this further 
confirmed that the competition association assay was a valid tool to determine the binding 
kinetics of unlabeled ligands for the hGnRH receptor (Figure 4A) and secondly, proved that 
equilibrium was reached for all agonists in the displacement experiments. The dissociation 
rates ranged from 0.2 ± 0.03 min-1 for goserelin to 0.01 ± 0.003 min-1 for buserelin, a variance 
of roughly 20-fold. Interestingly, three distinctive association patterns were obtained from the 
 
Figure 3: Competition association experiment 
with 125I-triptorelin in the absence or presence 
of 0.3, 1 or 3*Ki value of unlabeled triptorelin 
(A) or 1*Ki value of buserelin, leuprorelin or 
GnRH (B). Representative graphs from one 
experiment performed in duplicate (See Table 
2 for kinetic parameters). 
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competition association assays (Figure 3B). Firstly, an ‘overshoot’ in 125I-triptorelin 
association was observed for slowly dissociating compounds, such as buserelin. Secondly, 
we noticed a shallow increase in 125I-triptorelin association for rapidly dissociating 
compounds, such as GnRH, and lastly, no difference was observed in the shape of the 125I-
triptorelin association curve for equally fast-dissociating compounds, such as leuprorelin. The 
observed differences in dissociation kinetics were all in comparison to those of the 
radioligand 125I-triptorelin (Figure 3B). Association rates ranged from 0.8 ± 0.2 nM-1min-1 for 
nafarelin to 0.02 ± 0.004 nM-1min-1 for fertirelin, a span of approximately 35-fold.  
 
 
Figure 4: Correlation between affinities (pKi) and dissociation constants (pKD) 
derived from (A) radioligand binding (r2= 0.9, P<0.0001) and (B) TR-FRET 
experiments (r2=0.5, P<0.05). (C) Correlation between affinities (pKi) derived from 
radioligand binding and HTRF experiments (r2=0.5, P<0.05). (D) Correlation 
between dissociation constants (pKD) derived from radioligand binding and TR-FRET 
experiments (r2=0.8, P<0.001). In all cases, pKi values were obtained from 
equilibrium displacement studies and pKD values were determined with competition 
association experiments. 
 
Determination of the receptor binding kinetics of unlabeled hGnRHR agonists with a 




The kinetic parameters of the twelve GnRH agonists were also determined with TR-FRET 
experiments (Figure 5, Table 5 and Supplementary Figure 3). Association rates ranged from 
0.1 ± 0.02 nM-1min-1 for triptorelin to 0.02 ± 0.002 nM-1min-1 for histerelin. Buserelin was 
again one of the slowest dissociating agonists with a dissociation rate of 0.02 ± 0.003 min-1, 
while GnRH had the fastest dissociation rate of 0.4 ± 0.03 min-1. The dissociation constants 
(KD) calculated from kon and koff values were consistent with the affinities determined in HTRF 
displacement assays (Figure 4B) as well as with the KD values obtained from the radioligand 
binding studies (Figure 4D). Dissociation rate constants (koff) were in good agreement with 
the data obtained from radioligand binding experiments (r2=0.7, p<0.0005) (Figure 6A), while 
the association rates (kon) presented no correlation (r2=0.03, p=0.6) (Figure 6B).  
 
Discussion and Conclusions  
Over the years several studies have indicated that long duration of action is an 
important feature contributing to improved efficacy of drugs designed to treat chronic illness. 
Moreover, increased target-residence time offers the potential for a once-daily dosage form  
Table 4: Binding parameters of GnRH peptide agonists derived from radioligand binding and 
TR-FRET experiments 
 Radioligand binding  TR-FRET 
Agonist pKi and (Ki 
(nM)) 
pKD and (KD 
(nM)) 
pKi  and (Ki 
(nM)) 
pKD and (KD 
(nM)) 
GnRH 7.9 ± 0.05 (13) 8.5 ± 0.08 (2.9)  8.4 ± 0.6 (4.0) 7.7 ± 0.03 (22)  
Triptorelin 9.6 ± 0.09 (0.3) 9.7 ± 0.1 (0.2)  9.5 ± 0.2 (0.4) 9.5 ± 0.03 (0.4)  
[D-Ala6]-GnRH 9.0 ± 0.05 (0.8) 9.1 ± 0.09 (0.8)  8.6 ± 0.4 (2.3) 8.9 ± 0.02 (1.3)  
[D-Lys6]-GnRH 8.3 ± 0.1 (5.2)  8.4 ± 0.2 (3.7)# 7.8 ± 0.3 (16) 7.8 ± 0.01 (15)  
Fertirelin 9.2 ± 0.05 (0.7) 9.1 ± 0.08 (0.8)#  9.0 ± 0.3 (1.0) 9.0 ± 0.02 (0.9)  
Alarelin 9.4 ± 0.1 (0.5) 9.8 ± 0.1 (0.2)  9.0 ± 0.3 (0.9) 9.4 ± 0.03 (0.4)  
Deslorelin 10 ± 0.1 (0.1) 9.9 ± 0.1 (0.1) # 8.6 ± 0.6 (0.8) 9.4 ± 0.04 (0.4)  
Leuprorelin 9.5 ± 0.09 (0.3) 9.8 ± 0.1 (0.2)  9.7 ± 0.3 (0.2) 8.9 ± 0.03 (1.2)  
Nafarelin 10 ± 0.06 (0.06) 10.6 ± 0.1 (0.03)  9.8 ± 0.3 (0.2) 9.7 ± 0.06 (0.2)  
Buserelin 9.9 ± 0.05 (0.1) 10.4 ± 0.2 (0.04)  9.4 ± 0.2 (0.4) 9.5 ± 0.04 (0.3)  
Goserelin 8.8 ± 0.06 (1.6) 9.0 ± 0.08 (1.1)  9.1 ± 0.3 (0.9) 8.6 ± 0.02 (2.7)  
Histerelin 9.8 ± 0.2 (0.2) 10 ± 0.08 (0.04)  8.7 ± 0.5 (1.9) 9.0 ± 0.04 (1.0)  
Values are means ± SEM of at least three separate experiments performed in duplicate. #Values 
are means ± SEM of two separate experiments performed in duplicate. KD = koff/kon 
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that increases patient compliance 
which is crucial for the management of 
diseases [1, 2, 5, 36-40].   
The GnRH receptor is the target 
of multiple marketed peptide agonists, 
classified as functional antagonists, used 
to treat hormone-dependent diseases. 
Available patient information for the most 
commonly prescribed GnRH analogues 
suggests that the PK/PD profiles are very 
similar. Hence, knowledge of the in vitro 
binding kinetics could give extra insights 
into these well-known drugs. However, 
the potential impact of variable binding 
kinetics of these GnRH peptide 
derivatives on clinical efficacy has not 
been investigated. Aside from agonists, a 
few studies have detailed the effect of 
slow dissociation kinetics of  
antagonists for the GnRH 
receptor to decrease the maximal 
response of an agonist 
(insurmountability) in vitro and to improve 
and prolong efficacy in vivo. A study of Kohout and coworkers [25] addressed the 
insurmountability of a small molecule GnRH antagonist, TAK-013. The authors examined the 
differences in antagonistic and kinetic properties of TAK-013 for hGnRHR, mouse GnRHR 
(mGnRHR) and mutated mGnRHR and found a good correlation between the degree of 
insurmountability in in vitro functional assays and the dissociation rate from the receptor. 
Therefore, they proposed slow receptor dissociation kinetics to be accountable for the 
mechanism of insurmountability of TAK-013. Similar findings were published [24] for another 
series of small molecule antagonists, i.e. uracils. Slowly dissociating ligands displayed 
insurmountable antagonism whereas faster dissociating ligands proved to be surmountable 
antagonists. To determine the dissociation rates of these uracil-series of antagonists the 
competition association method [33] was used with a proprietary small molecule radioligand 
as a tracer. Such a competition association assay  has recently been applied to determine 
the receptor kinetics of ligands for several different GPCRs such as the adenosine A2A 
receptor [41], the muscarinic M3 receptor [42], the chemokine receptor CCR2 [43] and the 
 
Figure 5: Competition association experiment 
with fluorescent probe in the absence or 
presence of increasing concentrations of 
buserelin (A) or one-concentration of unlabeled 
agonist that showed around 50% displacement 
(B). Representative graphs from one experiment 
performed in quadruplicate. 
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histamine H1 and H3 receptor [44]. We were able, for the first time, to determine the kinetic 
parameters of twelve GnRH peptide agonists, including many marketed drugs.  
Two different techniques were applied, 
namely; radioligand binding studies and kinetic 
probe competition assays (kPCA) with a TR-
FRET read-out. For the former, a comparison of 
the radioligand’s kinetic parameters obtained 
from traditional radioligand binding experiments 
showed a good consistency with the kinetic 
parameters for triptorelin derived from the 
competition association assay (Table 2). 
Moreover, the kinetics of the 11 remaining 
GnRH agonists presented a good correlation 
between the kinetically derived KD and the 
affinity obtained from equilibrium radioligand 
binding studies (Figure 4). Secondly, we also 
conducted these experiments with a 
fluorescently labeled buserelin probe in a TR-
FRET assay. This technology has already been 
used for examining equilibrium GPCR ligand 
binding [45, 46] and more recently it was used 
to characterize the binding kinetics of the 
Histamine H1 receptor [34].  
Comparing affinities and kinetic KD 
values from both the radioligand binding and 
TR-FRET assays yielded significant correlations demonstrating a good reproducibility 
between both techniques. The two distinct assays also proved to be very amenable to the 
determination of the kinetic receptor binding parameters of (peptide) GnRH agonists. 
Dissociation rates, and thus residence times, between assays were in good accordance with 
p values of <0.0005, while the association rates were in less agreement between techniques. 
It should be noted that the experimental differences between both assays are considerable, 
which may have consequences for the kinetic parameters derived in the two assays. For 
example, the radioligand binding studies were manually dispensed while the TR-FRET 
assays were performed using automated dispensing devices. It has been reported that 
compound handling can be an important source of assay variability [47]. In addition, the 
kinetic binding parameters were determined using a one-concentration method for the 
 
Figure 6: Correlation between the kinetic 
parameters obtained from radioligand 
binding assays and kPCA TR-FRET 
experiments. (A) Dissociation rate (koff) 
(r2=0.7, P<0.0005); (B) association rate 
(kon) (r2=0.03, P=0.6). 
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radioligand binding experiments whereas the kPCA studies used five different 
concentrations.  
 
Another notable difference is that in the radioligand binding studies CHOhGnRH 
membranes were used whereas the TR-FRET assays were performed with Tag-lite™ HEK293 
GnRH cells. Packeu et al. discussed the differences in membrane interactions of membrane 
preparations and whole cells and their effects on binding kinetics for the D2L-dopamine 
receptors [48]. Moreover, the authors found slower dissociation rates from intact cells in 
comparison to membrane preparations and they proposed that an intact cellular environment 
could play a role in stabilizing the D2L-dopamine receptors in a particular conformation. A 
similar reasoning might be applicable to the GnRH receptor, although in our case the 
receptor appears in a way that slows down the association rates of the peptides (Table 5). It 
Table 5:  Kinetic receptor binding parameters of GnRH peptide agonists derived from radioligand 
binding competition association assays and kPCA TR-FRET experiments 
 Radioligand binding  TR-FRET 
Agonist kon (nM-1min-
1)a 
koff (min-1)a RT (min)c kon (nM-1min-
1)b 
koff (min-1)b RT 
(min)c 
GnRH 0.06 ± 0.01 0.2 ± 0.02 6.3 ± 0.6  0.02 ± 0.01 0.44 ± 0.3 2.3 ± 1.6 
Triptorelin 0.1 ±  0.01 0.03 ± 0.008 39 ± 12  0.1 ± 0.02 0.05 ± 0.008 21 ± 3.7 
[D-Ala6]-
GnRH 
0.08 ± 0.01 0.07 ± 0.01 15 ± 3.1  0.05 ± 0.007 0.07 ± 0.01 14 ± 2.3 
[D-Lys6]-
GnRH 
0.04 ± 0.02# 0.1 ± 0.04#  7.7 ± 2.3# 0.02 ± 0.01 0.25 ± 0.17 4 ± 2.6 
Fertirelin 0.02 ± 0.004#  0.02 ± 0.001# 56 ± 3.1# 0.07 ± 0.009 0.06 ± 0.01 15 ± 2.4 
Alarelin 0.09 ± 0.02 0.01 ± 0.002 77 ± 12  0.09 ± 0.009 0.03 ± 0.005 31 ± 4.8 
Deslorelin 0.07 ± 0.01#  0.01 ± 0.002# 100 ± 20# 0.05 ± 0.005 0.02 ±0.004 44 ± 6.9 
Leuprorelin 0.2 ± 0.04 0.03± 0.005 36 ± 6.4 0.03 ± 0.004 0.04 ± 0.006 26 ± 4.4 
Nafarelin 0.8 ± 0.2  0.02 ± 0.003  50 ± 7.5  0.1 ± 0.02 0.03 ± 0.006 39 ± 9.8 
Buserelin 0.2 ± 0.06 0.009 ± 0.003  111 ± 37  0.05 ± 0.004 0.02 ± 0.003 61 ± 10 
Goserelin 0.2 ± 0.002 0.2 ± 0.03 5.6 ± 0.8 0.03 ± 0.005 0.08 ± 0.01 13 ± 2.4 
Histerelin 0.3 ± 0.04 0.01 ± 0.002 83 ± 14 0.02 ± 0.002 0.02 ± 0.004 50 ± 8.8 
Values are means ± SEM of at least three separate experiments performed in duplicate. #Values are 
means ± SEM of two separate experiments performed in duplicate. akon and koff of unlabeled GnRH 
agonists were determined at 1-fold Ki concentrations. bkon and koff of unlabeled GnRH agonists were 
determined at 0.5, 5, 50 and 500 nM. cRT = 1/koff 
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may also be that the peptides simply have more difficulty in reaching the receptor on intact 
cells than on membrane fragments. 
It might be argued that the assay temperature of 25 °C is not representative for 
binding kinetics observed in vivo.  For example, Sakai [49] examined the effect of 
temperature on the dissociation of 125I-prolactin from the rabbit mammary gland prolactin 
receptor. They found a linear relationship between the dissociation rate and temperature with 
an increased dissociation rate at higher temperatures. Another study [50] also showed that 
the dissociation of [3H]-QMDP from the histamine H1 receptor was temperature-dependent, 
which was also true for the association rate but to a lesser extent. Arrhenius plots for both 
the association rate and dissociation rate of [3H]-QMDP were linear between 6 °C and 37 °C. 
It should be noted that, although these studies show a linear increase in dissociation rates 
with higher temperatures the slope of this increase could be very different between targets 
and their ligands. Taken together, this indicates that the kinetic ranking of ligands for the 
same receptor can be expected to stay the same over different temperatures. Therefore, 
even though all our experiments were performed at 25 °C, the results are still of great value 
for translation to in vivo outcomes. 
Numerous peptide GnRH derivatives have been synthesized and studied for their so-
called structure-affinity relationships (SAR), with the aim to improve their affinity, potency 
and/or metabolic stability [20-22, 51-53] In summary, it was established that the NH2-terminal 
domain (pGlu-His-Trp-Ser) of GnRH is important for receptor binding and activation with Trp3 
as a critical residue. In addition, the COOH-terminal domain (Pro-Gly-NH2) is crucial for 
receptor binding where substitution of Pro9 or removal of NH2 results in very low affinity 
unless the COOH-terminal tail is substituted for an ethylamide which also improves metabolic 
stability. In contrast, the central domain of the peptide is less conserved and studies show 
that exchange of Tyr5, Leu7 or Arg8 is mostly well tolerated. The most beneficial substitution 
is that of Gly6 with a D-amino acid which provides a more favorable conformation and in turn 
results in increased potency. D-amino acids at the 6th position of the peptide are therefore 
incorporated in all marketed GnRH analogues. The amino acid sequences of the twelve 
GnRH peptides tested in this study are identical with the exception of the 6th amino acid and 
the carboxylic tail (Table 1). A tentative structure kinetic relationship (SKR) could be 
established for the carboxylic tail (i.e. substitution of the glycine-amide for an ethylamide). 
For instance, a comparison of triptorelin and deslorelin showed 2/3-fold changes in affinity 
(Table 4), which was also observed in residence time. This ethylamide-induced improvement 
in residence time was also true to a bigger extent for goserelin and buserelin, where the 
affinity was improved 2- or 16-fold (TR-FRET and radioligand binding, respectively), while the 
residence time was more significantly affected, witnessed by a 5-fold increase in the kPCA 
TR-FRET experiments and a 20-fold increase in the radioligand binding studies. This shows 
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that shortening the carboxylic tail of the peptide slightly increases the affinity, but results in a 
more significant improvement in residence time. Interestingly, three decades ago it was 
already speculated that buserelin has a longer residence time. In these studies, the authors 
proposed that the high potency and long duration of action of buserelin in vivo was a result of 
prolonged GnRH receptor binding [54-56]. Along similar lines, Flanagan and coworkers 
discussed slower dissociation rates of GnRH agonists with a more hydrophobic amino acid at 
position 6 [57]. However, no mechanism or kinetic binding data was reported at that time.  
Previously published mutagenesis studies further strengthen our hypothesis 
indicating the importance of the ethylamide at the carboxylic tail. Davidson and coworkers 
showed that the Asn2.65(102)  residue located near the extracellular end of TM2 plays a role in 
ligand binding, specifically with the carboxylic tail of GnRH analogs [58]. Mutations to alanine 
at this position significantly decreased the potency of GnRH analogs with Gly10-NH2, but had 
a lesser effect on GnRH analogs with an ethylamide tail [21, 59, 60]. It may be hypothesized 
that substitution of Gly10-NH2 with an ethylamide moiety creates less steric hindrance and 
increases hydrophobicity, thereby improving the fit of the agonist and thus elongating its 
residence time on the receptor.  
In conclusion, two novel competition association assays were successfully developed 
and applied to determine the kinetic binding characteristics of twelve peptide agonists, 
including many marketed drugs targeting the GnRH receptor. All agonists proved to have 
high affinity for the GnRH receptor whereas significant differences were observed in their 
binding kinetics. These findings provide new insights and tools for the development of 
improved drugs targeting the GnRH receptor by incorporating optimized kinetic binding 
parameters. They also suggest that bringing this knowledge on kinetics to the clinic may help 
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Supplemental Data  
 
Supplementary Figure 1. Saturation equilibrium binding of 
fluorescent buserelin probe to Tag-lite™ GnRH cells (IC50 = 5.9 
nM, r2 = 0.99). Representative graph from one experiment 
performed in duplicate. 
 
 
Supplementary Figure 2. Association and dissociation kinetics of five 
concentrations of fluorescent buserelin probe to Tag-lite™ GnRH cells. 





Supplementary Figure 3. kPCA traces of the GnRH peptide agonists analyzed. Four 
concentrations (0.5, 5, 50 and 500 nM) were examined. Representative graphs from one 
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 The gonadotropin-releasing hormone (GnRH) receptor is a drug target for certain 
hormone-dependent diseases such as prostate cancer. In this study, we examined the 
activation profiles of the endogenous ligand, GnRH and a well-known marketed analog, 
buserelin using a label-free assay in pituitary αT3-1 cells with endogenous GnRH receptor 
expression. This whole cell impedance-based technology allows for the real-time 
measurement of morphological cellular changes. Both agonists dose-dependently de- 
creased the impedance as a result of GnRH receptor activation with potencies of 9.37 ± 0.1 
(pEC50 value, buserelin) and 7.87 ± 0.06 (pEC50 value, GnRH). Subsequently, GnRH 
receptor activation was completely abolished with a selective Gαq inhibitor, thereby 
confirming the Gαq-coupling of the GnRH receptor in pituitary αT3-1 cells. Additionally, we 
observed continued responses after agonist stimulation of αT3-1 cells indicating long-lasting 
cellular effects. Wash-out experiments demonstrated that the long-lasting effects induced by 
GnRH were most likely caused by rebinding since over 70% of the original response was 
abolished after wash-out. In contrast, a long receptor residence time was responsible for the 
prolonged effects caused by buserelin, with over 70% of the original response remaining 
after wash-out. In summary, we validated that impedance-based label-free technology is 
suited for studying receptor-mediated activation in cell lines endogenously expressing the 
target of interest. Moreover, this real-time monitoring allows the examination of binding 




Label-free technologies can noninvasively monitor real-time receptor-mediated 
phenotypic responses in living cells encompassing all involved signaling pathways [1, 2]. 
Label-free whole cell assays typically use a biosensor to detect a ligand-induced cellular 
response by ways of acoustic, electrical or other quantifiable signals [3, 4]. The main 
advantage of using biosensors and cell morphology as a readout is that cells can be 
assessed in their native and physiologically relevant environment bypassing the potentially 
negative effects of engineering on cell signaling [5, 6].  Additionally, label-free assays are 
highly sensitive therefore making them suitable for endogenous expression systems. Label-
free studies are most commonly used to examine G protein-coupled receptor (GPCR) 
activation and G protein-signaling profiles [7-9], but also for investigating cytotoxicity, cell 
adhesion, proliferation, migration and invasion [6, 10, 11]. 
The gonadotropin-releasing hormone receptor (GnRHR) is part of the rhodopsin 
family of GPCRs and is sub-classified in the β-group where all endogenous ligands are 
peptides [12]. Its endogenous ligand, gonadotropin-releasing hormone (GnRH) is a 
decapeptide synthesized in hypothalamic neurons. GnRH regulates the synthesis and 
secretion of luteinizing hormone (LH) and follicle stimulation hormone (FSH) by selectively 
stimulating pituitary gonadotropes expressing the GnRH receptor [13]. The role of GnRHR in 
regulation of hormone levels in both males and females makes it an important target in 
hormone dependent diseases such as precocious puberty, fertility disorders and cancers of 
the prostate, mammary, ovary and endometrium [14, 15].  
In the current study we investigated GnRHR-induced signaling in a heterologous 
CHOhGnRH-NFAT cell line as well as the αT3-1 cell line using a label-free whole cell 
impedance-based assay. The gonadotrope mouse pituitary αT3-1 cell line [16] is known to 
have high endogenous GnRHR expression [17]. In the present study, we established that 
both the heterologous CHOhGnRH-FNAT cell line and the endogenous αT3-1 cell line are 
suitable to study GnRHR-mediated signaling using a label-free technology. In addition, we 
were able to, for the first time, elucidate the functional effects of GnRHR agonists with 
different binding kinetics. Taken together, we demonstrated the importance of monitoring 
integrated cellular responses to gain knowledge in receptor signaling and binding kinetics 
that cannot be detected with traditional endpoint assays.  
Methods 
Materials and reagents  
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GnRH, buserelin and cetrorelix were purchased from Sigma-Aldrich Chemie B.V. 
(Zwijndrecht, the Netherlands), while UBO-QIC was purchased from the Institute of 
Pharmaceutical Biology (University of Bonn, Germany). [2-3H(N)]-myoinositol (specific 
activity 10-25 Ci/mmol), isoplate-96™ white frame, clear well plates and YSi Poly-L-Lysine 
coated SPA beads were purchased from Perkin Elmer (Boston, MA). CHO cells stably 
expressing both the human GnRH receptor and an NFAT reporter gene (CHOhGnRH-NFAT) 
were obtained from Invitrogen (Carlsbad, CA). αT3-1 cells were a kind gift from Dr. Pamela 
L. Mellon (Salk Institute, San Diego, CA). xCELLigence E-plate 16 and 96 were obtained 
from Westburg (Leusden, the Netherlands). All other compounds and materials were 
obtained from standard commercial sources. 
Cell culture 
CHOhGnRH-NFAT cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% dialyzed fetal calf serum (FCS), 25 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 100 µg/ml zeocin, 600 µg/ml hygromycin, 100 
IU/ml penicillin and 100 mg/ml streptomycin at 37 °C + 5% CO2. αT3-1 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal calf serum 
(FCS), 4.5 g/L glucose, 548 mg/L L-glutamine, 110 mg/L pyruvate, 100 IU/ml penicillin and 
100 mg/ml streptomycin at 37 °C + 5% CO2. Cells were cultured as a monolayer and used 
for whole cell experiments when a confluency of ~75% was reached. 
Label-free whole-cell assays 
Label-free whole-cell assays were performed using the xCELLigence RTCA system 
[5, 6] as described previously [18].  
CHOhGnRH-NFAT cells and αT3-1 cells were cultured as a monolayer on 10-cm ø 
culture plates and were harvested when confluency was around 75%. The experiment was 
started by adding 45 µl culture medium to each well to obtain background signal. 
Subsequently, 50 µl of cell suspension containing 1.6*106 cells/ml was added to each well to 
obtain approximately 40.000 cells/well. After roughly 18 hours on the recording device station 
in a humidified atmosphere at 37°C + 5% CO2, cells were stimulated with increasing 
concentrations of GnRH, buserelin or vehicle control. For antagonistic assays, background 
signal was obtained with 40 µl culture medium/well and cells were incubated with an excess 
of the antagonist cetrorelix (160 nM) or vehicle control 30 min prior to stimulation with 
submaximal (EC80) concentrations of GnRH (31.6 nM) or buserelin (1 nM). For inhibition of 
the Gαq signaling pathway, αT3-1 cells were pretreated with 1 µM UBO-QIC or vehicle 
control 30 min prior to stimulation with submaximal (EC80) concentrations of GnRH (31.6 nM) 
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or buserelin (1 nM). Submaximal (EC80) concentrations of GnRH and buserelin were derived 
from concentration-response curves using Total Area Under the Curve (AUC) analysis (see 
section ‘Data analysis’). 
Inositol phosphate accumulation assay 
αT3-1 cells were seeded at a cell density of  100.000 cells/well with [3H]-myoinositol 
(4 µCi/ml) overnight at 37°C and 5% CO2. Subsequently, cells were washed twice with Buffer 
A containing 127 mM NaCl, 5 mM KCl,  2 mM MgCl2, 0.5 mM NaH2PO4, 5 mM NaHCO3, 1.8 
mM CaCl2, 10 mM HEPES  and 0.1% BSA. Thereafter, cells were incubated for 20 minutes 
at 37 °C with Buffer A supplemented with 50 mM LiCl, followed by stimulation with increasing 
concentrations of GnRH or buserelin for 60 min at 37°C. Cells were lysed through 1 hour 
incubation with 10 mM formic acid at 4°C, after which 20 µL of solution was transferred to an 
isoplate™ 96 followed by addition of 80 µL YSi Poly-L-Lysine-coated SPA beads at 12 
mg/ml. The mixture was shaken at room temperature for 60 min prior to a 5 min centrifuge 
step at 1500 rpm. Radioactivity of the extract/bead mixture was determined by scintillation 
spectrometry using the P-E 1450 Micobeta Wallac Trilux scintillation counter according to 
instruction manual (Perkin Elmer, Groningen, the Netherlands).  
Data analysis 
All experimental data were analyzed using GraphPad Prism 5.0 (GraphPad Software 
Inc., San Diego, CA). Cell index (CI) traces were normalized to time of agonist addition and 
then exported from RTCA Software 1.2 (Roche, Germany). Total AUC values up to 180 min 
after agonist addition were used for data analyses. Baseline was removed by subtracting 
vehicle, antagonist and inhibitor controls from corresponding normalized CI (NCI) traces.  
Efficacy (Emax) and potency (pEC50) values for GnRH and buserelin were obtained 
with non-linear regression of Total AUC data fitted by log(agonist) vs. response - Variable 
slope. Results were normalized to Total AUC induced by the maximal concentration of 
GnRH. Total AUC of agonist-induced cellular responses in presence of antagonist or 
pathway inhibitor were normalized to Total AUC obtained from αT3-1 cells responses treated 
with submaximal concentrations (EC80) of corresponding agonist.  
Efficacy (Emax) and potency (pEC50) values for IP accumulation assay were obtained 
using non-linear regression of total counts upon GnRH or buserelin-induced Gαq-activation 
fitted by log(agonist) vs. response - Variable slope. Results were normalized to total counts 
induced by the maximal concentration of GnRH.  
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All values obtained are means ± SEM of at least three independent experiments 
performed in duplicate.  
 
Figure 1: Real-time monitoring of the cell index as a measure of proliferation and adherence 
of CHOhGnRH-FNAT cells (A) and αT3-1 cells (B) before and after (18 h) addition of 1  µM  
GnRH. Zoom in on the effect of GnRH yielding the normalized cell index after addition of 1 
µM GnRH to CHOhGnRH-NFAT cells (C) and αT3-1 cells (D). 
 
Results 
GnRHR signaling in heterologous and endogenous cells on the xCELLigence 
Heterologous GnRH receptor-mediated signaling in CHOhGnRH-NFAT cells was 
monitored on the xCELLigence system. Overnight proliferation resulted in a cell index of 
approximately 4.0 (Figure 1A). Typically, the impedance increased upon agonist addition with 
a first peak around 10 min of approximately 0.075 NCI, followed by a second peak reaching 
approximately 0.15 NCI around 80 minutes. The signal decreased again back to baseline 
after approximately 180 min (Figure 1C).  
Stimulation of CHOhGnRH-NFAT cells with increasing concentrations of GnRH and 
its analog buserelin resulted in a concentration-dependent increase in impedance (Figure 2A 
and 2C). From these impedance changes a concentration-response curve could be obtained 
providing pEC50 values of 10 ± 0.1 and 10.6 ± 0.2 for GnRH and buserelin, respectively 
(Figure 2E and Table 1). The efficacy of buserelin was similar to that of GnRH, namely 98 ± 
4.5% (Table 1). To confirm that the observed changes in impedance are GnRHR-specific the 
77 
 
parental CHO cell line was used as a negative control. Treatment of these cells with 1 µM of 
GnRH did not result in a change in impedance (Figure 3A and 3D). Additionally, the selective 
GnRH peptide antagonist cetrorelix was able to block receptor activation by GnRH (Figure 
3B and 3D). 
Table 1: potency and efficacy of GnRH and buserelin obtained with xCELLigence and IP 
accumulation experiments performed with CHOhGnRH-NFAT and αT3-1 cells.  
Agonist CHOhGnRH-NFAT  αT3-1  
(xCELLigence#) (xCELLigence#) (IP accumulation) 
 pEC50  
(EC50 in nM) 
Emax (%) pEC50  
(EC50 in nM) 
Emax (%) pEC50  
(EC50 in nM) 
Emax (%) 
GnRH 10 ± 0.1 (0.1) 100 ± 3 7.8 ± 0.06 (17) 100 ± 1 7.9 ± 0.2 (12) 100 ± 0.9 
Buserelin 10.6 ± 0.2 (0.03) 98 ± 5 9.3 ± 0.1 (0.46) 90 ± 3* 10 ± 0.1 (0.09) 115 ± 1*** 
Values are means ± SEM of three separate experiments performed in duplicate. # Values were 
calculated with total AUC analysis up to 180 min after agonist addition. Data were normalized to 
maximal response obtained for GnRH. *=p>0.05, ***=p>0.0005, compared to Emax GnRH determined 
with Student’s t test. 
 
To examine if the GnRHR-mediated responses in the heterologous cell line could also 
be observed in the endogenous pituitary αT3-1 cell line, we studied GnRH signaling with the 
xCELLigence on this cell line. Overnight proliferation gave a cell index of roughly 3.0 (Figure 
1B). In contrast to the effect on CHOhGnRH-NFAT cells, addition of 1 µM GnRH resulted in a 
decrease in impedance reaching and maintaining its plateau around 0.4 NCI within 1 hour up 
to but not limited to 180 min after stimulation (Figure 1D).  
Addition of increasing concentrations of GnRH and buserelin resulted in a 
concentration-dependent decrease in impedance (Figure 2B and 2D). Interestingly, low 
concentrations of both GnRH and buserelin resulted in a positive NCI. The concentration-
response curves gave an EC50 value of 17 nM for GnRH and a 37-fold lower EC50 value of 
0.46 nM for buserelin (Figure 2F and Table 1). Buserelin had a slightly, yet significantly, 
lower efficacy than GnRH of 90 ± 3.1%. The GnRHR-mediated responses were selectively 
blocked by pretreatment with the GnRH peptide antagonist cetrorelix (3.8 ± 0.3%), supportive 
of a receptor-specific effect (Figure 3C, 3D). Since the xCELLigence detects morphological 
changes rather than one specific intracellular signaling pathway following GPCR activation 
we suppressed Gαq-mediated signaling with inhibitor UBO-QIC prior to GnRH treatment. This 
selective inhibition of the Gαq pathway completely abolished GnRHR activation (3.8± 1.6%) 




Figure 2:  Concentration-dependent effects of GnRH and buserelin on CHOhGnRH-NFAT 
(left) and αT3-1 (right) cells. Representative graph of one experiment performed in duplicate 
of normalized cell index (NCI) after stimulation with increasing concentrations of GnRH (A; 
CHOhGnRH and B; αT3-1) or buserelin (C; CHOhGnRH and D; αT3-1). Representative 
concentration-effect curve of GnRH and buserelin derived from total AUC up to 180 min 
after agonist stimulation, data were normalized to maximal response after GnRH stimulation 
(E; CHOhGnRH and F; αT3-1). 
 
GnRHR signaling in pituitary αT3-1 cells using second messenger assays 
 To compare our obtained potency and efficacy values for GnRH and buserelin to a 
more traditional second messenger assay we examined IP accumulation in αT3-1 cells upon 
GnRHR-activation which is a consequence of activating the Gαq pathway. Concentration-
response curves of GnRH and buserelin yielded pEC50 values of 7.9 ± 0.2 and 10 ± 0.1, 
respectively (Supplementary Figure 1). In this assay, buserelin showed a significant increase 
in efficacy namely 115 ± 1% (Table 1). 
 





GnRH and buserelin both showed sustained signaling on the xCELLigence, i.e. a 
decrease in impedance reaching and maintaining its plateau around 0.4 NCI within 1 hour up 
to but not limited to 180 min after stimulation, which indicates long-lasting functional effects. 
To examine whether these effects were due to a long drug-target residence time we 
performed a washout experiment. Thirty minutes after stimulating with EC80 concentrations of 
GnRH or buserelin, cells were washed followed by further label-free measurements (Figure 
4A). Washout after stimulating the cells with GnRH or buserelin decreased the response 
relative to unwashed conditions to 43 ± 6% or 79 ± 5% after 30 min, respectively (Figure 4B 
 
Figure 3: GnRHR mediated responses in parental CHO cells, CHOhGnRH-NFAT cells or 
αT3-1 cells. Representative graph of one experiment performed in duplicate of normalized 
cell index (NCI) after stimulation with GnRH of parental CHO cells (A), CHOhGnRH-NFAT 
cells (B) or αT3-1 cells (C) with or without pretreatment with cetrorelix or αT3-1 cells (D) with 
or without pretreatment with UBO-QIC. Bar graph of total AUC up to 180 min of cells 
stimulated with GnRH with or without 160 nM cetrorelix or 1 µM UBO-QIC pretreatment in 
αT3-1 cells (green), CHOhGnRH-NFAT cells (red) or parental CHO cells (blue), data were 
normalized to maximal response after GnRH stimulation without inhibitor (E).  
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and Table 2). The response continued to decline after 120 minutes for GnRH (27 ± 7%) 
whereas buserelin remained active at approximately 80% of the control activation (Figure 4B 
and Table 2).  
Discussion 
Label-free impedance-based xCELLigence is suitable to study GnRHR activation  
 
Label-free whole cell assays 
provide new perspectives in studying 
GPCR signaling by continuously 
measuring cell morphology changes 
upon receptor activation [2, 6, 8, 9]. 
These novel phenotypic functional 
assays have many advantages over 
traditional endpoint assays, as they 
measure integrated cellular responses 
rather than signals downstream one 
particular G protein pathway. Label-
free whole cell assays thus 
encompass a complete overview of 
cellular function and responses after 
receptor activation. Here, we 
demonstrate for the first time signaling 
of the GnRH receptor using the label-
free whole cell impedance-based 
xCELLigence system in heterologous 
CHOhGnRH-NFAT cells as well as 
endogenous gonadotrope pituitary 
αT3-1 cells.  
Initial experiments with 
CHOhGnRH-NFAT cells demonstrated 
that the xCELLigence system is 
suitable to study GnRHR-mediated 
responses in a heterologous 
expression system. Concentration-response curves provided a pEC50 value of 10 ± 0.1 for 
GnRH, which is comparable to previously reported data [19]. Control experiments with the 
parental CHO cell line and the selective GnRHR peptide antagonist cetrorelix showed 
 
Figure 4: Wash out of αT3-1 cells stimulated with 
GnRH or buserelin. (A) Representative graphs of 
one experiment performed in duplicate after 
stimulation with either GnRH or buserelin (control) 
or followed by wash out at 30 min indicated by 
vertical dashed line (wash). (B) Bar graph of 
normalized cell index agonist induced effects 0 
min, 30 min and 120 min after wash out (B). Data 
are mean ± SEM from three separate experiments 
performed in duplicate. Data were normalized to 
maximal response obtained before wash out, 




absence of GnRHR responses, further verifying that the observed responses were GnRHR-
mediated. 
Subsequent experiments established that the endogenous pituitary αT3-1 cell line is 
also well suited for studying GnRHR signaling on the xCELLigence. GnRH-mediated signals 
were selectively blocked by the peptide antagonist cetrorelix, confirming the agonist 
responses were GnRHR specific. Additionally, we observed that silencing of the Gαq pathway 
with the selective inhibitor UBO-QIC completely abrogated agonist-mediated αT3-1 cell 
responses. This illustrates that GnRH and buserelin signal through the Gαq pathway, which is 
in agreement with previously reported data [14, 20-22].  
Considering that the 
endogenous mouse pituitary αT3-1 cell 
line is derived from immortalized 
anterior pituitary gonadotrope cells [16] 
and the mouse and human GnRHR are 
99 % homologous, all further 
experiments were continued with the 
endogenous pituitary αT3-1 cell line.  
 
Two well-known GnRH receptor 
agonists were studied in this research; 
the endogenous ligand GnRH and 
buserelin a GnRHR agonist that slowly 
dissociates from the receptor [23]. In 
the label-free whole cell assays both 
agonists were able to activate the 
GnRH receptor in a concentration-
dependent manner, albeit that buserelin 
had a 37-fold higher potency than GnRH (0.46 nM and 17 nM, respectively). Similar findings 
were observed in more traditional IP accumulation assays; here buserelin was 133-fold more 
potent than GnRH (0.09 nM and 12 nM, respectively). A much smaller (7-fold) potency shift 
between GnRH and buserelin has been reported before (3.4 nM and 0.47 nM) with total 
inositol phosphate production measurements using αT3-1 cells [24]. A possible explanation 
could be that the incubation time in their assay was only 30 min, which could result in an 
underestimated potency since buserelin might not yet have reached equilibrium. In our 
hands, the potency of GnRH was in the same range between the impedance-based and IP 
accumulation assays while buserelin was 5-fold more potent in the latter. Differences in 
Table 2: Receptor activation after wash out of 
EC80 concentrations of GnRH or buserelin 




0 min 100 ± 13 100 ± 8 
+ 30 min 43 ± 6*** 79 ± 5 
+ 120 min 27 ± 7**** 71 ± 8* 
Values are means ± SEM of three separate 
experiments performed in duplicate. Cells were 
washed after 30 min agonist stimulation and values 
were calculated using normalized cell index at 0 min, 
30 min and 120 min after wash out. Data were 
normalized to maximal response obtained before wash 
out, indicated as ‘’0 min’’. *= p<0.05, ***= p<0.001, ****= 
p<0.0001, compared to 0 min determined using one-
way ANOVA with Dunnett’s post-test. 
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potency between label-free whole cell assays and traditional second messenger functional 
assays have been observed before [25-28].  
 
Long-lasting residence time can be translated to a persistent activation profile in vitro 
In contrast to previously published xCELLigence data on GPCR activation [25, 29], 
we observed long-lasting signaling events of GnRH and buserelin on αT3-1 cells implying 
persisted GnRHR activation. This finding might be explained by either rebinding of the 
agonist to the receptor or long-lasting target binding [30]. Long-lasting target residence time 
has already been reported for buserelin, however GnRH was found to have a shorter 
residence time [23]. It has been postulated that the in vivo high potency and long duration of 
action of buserelin was caused by long-lasting GnRH receptor binding [31-33]. Therefore, we 
hypothesized that the long-lasting effects caused by GnRH are due to rebinding of this 
molecule to the receptor while the long-lasting effects caused by buserelin are a result of this 
compound’s prolonged target binding. To test this hypothesis we designed a washout 
experiment to minimize rebinding where we examined the remaining cellular response by 
GnRH and buserelin after washing. Wash out of GnRH or buserelin at EC80 concentrations 
showed a decreased signaling response for both agonists. Conversely, this decreased 
response in signaling was much more outspoken for GnRH than for buserelin. These results 
confirm our hypothesis, being that the observed persisted signaling profile of GnRH was due 
to rebinding while the persisted signaling profile of buserelin is a combination of both 
rebinding and prolonged drug-target occupancy caused by long drug-receptor residence 
time. Casarosa et al. [34], reported on a washout second messenger assay, examining 
cAMP production. In this assay the long residence time β2 adrenoceptor (β2-AR) agonist 
olodaterol remained associated with the receptor, while the short residence time β2-AR 
agonist salbutamol was readily washed out. Lindstrom and coworkers performed washout 
experiments with U373MG cells endogenously expressing the Tachykinin 1 receptor (NK1R) 
measuring intracellular Ca2+ levels. They demonstrated that the response to the endogenous 
agonist Substance P was not restored after a 60 min wash out of the slowly dissociating 




We have validated the label-free whole cell xCELLigence system as a valuable 
biosensor to investigate GnRHR-mediated signaling in endogenous pituitary αT3-1 cells. For 
the first time in a label-free assay environment we showed prolonged receptor signaling due 
to drug-target binding kinetics by wash out experiments. Our results illustrate the importance 
of monitoring phenotypic and integrative responses using label-free whole cell assays, since 
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traditional end-point assays are less suited to acquire information on drug-target binding 
kinetics in real-time. Incorporating whole cell label-free technologies in drug development will 
provide a more complete overview of the functional properties of a ligand and hopefully 
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Supplementary Figure 1: Concentration-dependent effects of 
GnRHR agonists in αT3-1 cells. IP accumulation upon stimulation 
with increasing concentrations of GnRH (red) or buserelin (blue). A 
representative graph is shown of one experiment performed in 
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Ligand-receptor binding kinetics (i.e. association and dissociation rates) are emerging 
as important parameters for drug efficacy in vivo. Awareness of the kinetic behavior of 
endogenous ligands is pivotal, as drugs often have to compete with those. The binding 
kinetics of neurokinin 1 (NK1) receptor antagonists have been widely investigated while 
binding kinetics of endogenous tachykinins have hardly been reported, if at all. Therefore, the 
aim of this research was to investigate the binding kinetics of endogenous tachykinins and 
derivatives thereof and their role in the activation of the NK1 receptor.   
We determined the binding kinetics of seven tachykinins targeting the NK1 receptor. 
Dissociation rate constants (koff) ranged from 0.026 ± 0.0029  min-1 (Sar9, Met(O2)11-SP) to 
0.21 ± 0.015 min-1 (septide). Association rate constants (kon) were more diverse: substance P 
(SP) associated the fastest with a kon value of 0.24 ± 0.046 nM-1 min-1 while neurokinin A 
(NKA) had the slowest association rate constant of 0.001 ± 0.0002 nM-1 min-1. Kinetic binding 
parameters were highly correlated with potency and maximal response values determined in 
label-free impedance-based experiments on U-251 MG cells.  
Our research demonstrates large variations in binding kinetics of tachykinins which 
correlate to receptor activation. These findings provide new insights in the ligand-receptor 
interactions of tachykinins and underline the importance of measuring binding kinetics of both 




Ligand-receptor binding kinetics are reflected by the association and dissociation 
rates of a ligand to and from its receptor. These kinetic parameters are increasingly 
acknowledged as a key player in drug-target interactions and functional effects in vivo [1-5]. 
Understanding of desired binding kinetics of a drug for the target of interest is crucial for 
efficient and efficacious drug development. For example, for the muscarinic M3 receptor a 
slow drug-target dissociation rate is desirable to achieve prolonged in vivo efficacy and better 
patient compliance [6]. In contrast, for the dopamine D2 receptor a fast dissociation rate is 
desired to minimize on-target side effects [7]. Notably, the majority of successful drugs 
achieve their potency by competing with endogenous ligands for the same orthosteric 
binding site. Therefore, knowledge of the pharmacological behaviour of endogenous ligands 
could benefit the understanding of desirable binding kinetics of competing drugs for the 
target of interest. 
The tachykinin receptor family consists of three neuropeptide G protein-coupled 
receptors (GPCRs), the neurokinin 1 receptor (NK1R), neurokinin 2 receptor (NK2R) and 
neurokinin 3 receptor (NK3R). The endogenous ligands for these receptors are substance P 
(SP), neurokinin A (NKA), neurokinin B (NKB). Each endogenous tachykinin has a specific 
rank order to activate tachykinin receptors with regards to potency and affinity, namely 
SP>NKA>NKB for the NK1 receptor, NKA>NKB>SP for the NK2 receptor and NKB>NKA>SP 
for the NK3 receptor. In 2000, a fourth endogenous tachykinin was discovered, namely 
hemokinin-1 [8]. Tachykinin receptors and their endogenous ligands are distributed 
throughout the central and peripheral nervous system and play an important role in e.g. 
nociception, cell proliferation, smooth muscle contraction and inflammation [9-11].  
The neurokinin 1 receptor couples predominantly through the Gαq protein signaling 
pathway, but can also induce Gαs protein and β-arrestin signaling [12, 13]. Although a 
plethora of literature is available on G protein signaling of  NK1 peptide agonists [14-16] and 
binding kinetics of NK1 antagonists [17-19], the kinetic binding parameters of the most well-
known endogenous tachykinins (i.e. SP, NKA, NKB and Hemokinin-1) and their synthetic or 
truncated derivatives (i.e. septide, Pro9-SP, SP(4-11) and Sar9,Met(O2)11-SP) have rarely 
been reported, if at all. Therefore, our aim was to determine the binding kinetics of the afore 
mentioned tachykinins (Figure 1) by using a radiolabeled competition association assay. In 
an effort to correlate the binding kinetics to functional effects in vitro we used a label-free 
impedance-based assay to examine receptor activation in human astrocytoma U-251 MG 
cells endogenously expressing the NK1 receptor. This label-free system allows for the real-
time monitoring of phenotypic receptor-mediated responses encompassing the entire 
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signaling cascade which makes it a very suitable system for this target that has been proven 
to activate multiple downstream signaling pathways [20, 21].  
In summary, we have for the first time used a competition association assay to 
determine the binding kinetics of endogenous tachykinins and their most well-known 
derivatives.  In addition, we were able to correlate the binding kinetics to functional effects in 
vitro using a whole-cell label-free technology. Our research illustrates the importance of 
knowledge of the association and dissociation rates of endogenous tachykinins and their role 
in receptor activation.  
 
Figure 1: Amino acid sequences of the examined tachykinins. The differences between the 
peptides are expressed in green. Sar = methylated glycine, Met (O2) = oxidized methionine 
and pGlu = pyro-glutamic acid.  
 
Methods  
Reagents and peptides 
SP, hemokinin-1 and U-251 MG cells were purchased from Sigma-Aldrich (St. Louis, 
MO). NKA, NKB, septide, Pro9-SP, SP (4-11), Sar9,Met(O2)11-SP and antagonist SC203437 
were obtained from Bio-Connect (Huissen, The Netherlands). Aprepitant was a kind gift from 
Roche Innovation Center Basel (Basel, Switzerland) and protease inhibitors (complete mini 
93 
 
cocktail) were purchased from Roche Diagnostics (Mannheim, Germany). 
[3H][Sar9,Met(O2)11]SP (specific activity 25-55 Ci/mmol) was obtained from Perkin Elmer 
(Boston, MA). Chinese Hamster Ovary (CHO) cells stably expressing the human neurokinin 
1 receptor (CHOhNK1 cells) were kindly provided by AstraZeneca (Macclesfield, UK). 
xCELLigence E-plate 16 and 96 were purchased from Westburg (Leusden, the Netherlands). 
All other compounds and materials were obtained from standard commercial sources. 
Cell culture 
CHOhNK1 cells were cultured in Ham’s F12 medium supplemented with 10% fetal 
calf serum (FCS), 2 mM glutamine and 1 mg/ml G418 at 37 °C + 5% CO2. U-251 MG cells 
were cultured in Earle’s Minimal Essential Medium (EMEM) supplemented with 10% FCS, 1 
mM sodium pyruvate, 2 mM glutamine, 1% non-essential amino acids (NEAA), 100 IU/ml 
penicillin and 100 µg/ml streptomycin at 37 °C + 5% CO2. Membranes were prepared as 
described previously [22]. In short, CHOhNK1 cells were collected in 50 mM Tris HCl buffer 
(pH 7.4 at 25°C) supplemented with 2 mM MgCl2 and subsequently centrifuged twice at 100 
000x g in an Optima LE-80 K ultracentrifuge (Beckman Coulter, Fullterton, CA, USA) for 20 
min at 4°C.   
Radioligand equilibrium displacement assays 
Displacement experiments were carried out using CHOhNK1 membrane aliquots 
containing 5-15 µg protein in a total volume of 100 µL assay buffer (50 mM Tris HCl, pH 7.4 
at 25 °C, supplemented with 5 mM MgCl2 and protease inhibitor cocktail (1 tablet/10 ml)) at 4 
°C for 90 minutes. Ten concentrations of competing ligand were used in the presence of one 
concentration [3H][Sar9,Met(O2)11]SP (25 000 dpm, ~2.5 nM). This concentration ensured that 
total radioligand binding did not exceed 10% of that added to prevent ligand depletion. Non-
specific binding was determined in the presence of an excess amount of SC-203437 (10 
µM).  
Homologous displacement assays were performed using CHOhNK1 membrane 
aliquots containing 5-15 µg protein, incubating at 4 °C for 90 minutes. Ten concentrations of 
[Sar9,Met(O2)11]SP were used in the presence of four different concentrations 
[3H][Sar9,Met(O2)11]SP (i.e. 4 nM, 3 nM, 2 nM and 1 nM). 
The reactions were terminated by the addition of 1 mL ice-cold wash buffer (50 mM 
Tris HCl, pH 7.4 at 25 °C, supplemented with 5 mM MgCl2). Separation of bound from free 
radioligand was performed by rapid filtration through Whatman GF/C filters saturated with 
0.25% polyethylene imine (PEI) using a Brandel harvester. Filters were subsequently 
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washed three times with 2 mL ice-cold wash buffer. Filter bound radioactivity was determined 
using a liquid scintillation counter (Tri-Carb 2900 TR, PerkinElmer).  
Radioligand kinetic association and dissociation assays 
Association and dissociation experiments were performed similarly to Nederpelt et al. 
[22], using CHOhNK1 membrane aliquots containing 5-15 µg protein, incubating at 4 °C with 
one concentration [3H][Sar9,Met(O2)11]SP (25 000 dpm, ~2.5 nM). Total incubation time of 
association experiments was 120 min with different time intervals. For dissociation 
experiments membrane aliquots were pre-incubated for 90 min and dissociation was initiated 
by addition of 10 µM SC-203437. The amount of radioligand still bound to the receptor was 
measured for 240 min at different time points.  
 
Radioligand kinetic competition association assays 
The binding kinetics of unlabeled peptides were quantified as described previously  
[22], using CHOhNK1 membrane aliquots containing 5-15 µg protein, incubating at 4 °C with 
one concentration [3H][Sar9,Met(O2)11]SP (30 000 dpm, ~3 nM). Total incubation time of 
competition association experiments was 120 min with different time intervals. The assay 
was validated using three concentrations (0.3*IC50, 1*IC50 and 3*IC50) of [Sar9,Met(O2)11]SP 
while the binding kinetics of all remaining agonists were determined using a concentration 
where displacement of [3H][Sar9,Met(O2)11]SP at 120 min was between 40 and 60%.  
 
Label-free whole cell assays 
Label-free whole-cell assays were performed using the xCELLigence a real-time cell 
analyzer (RTCA) system as described previously [23]. In short, this assay utilizes electrical 
impedance to measure changes in cell morphology. 20 000 U-251 MG cells/well were 
seeded in E-plates covered with golden electrodes on the bottom of each well, 18 hours prior 
to stimulation with increasing concentrations of agonist or vehicle control. For antagonistic 
assays, cells were incubated for 30 min with an excess of selective NK1 antagonist 
aprepitant (1 µM)  prior to stimulation with submaximal (EC80) concentrations of agonist. 
Data analysis 
All experimental data were analyzed using the nonlinear regression curve-fitting 
program GraphPad Prism v. 6.00 (GraphPad Software Inc., San Diego, CA). Radioligand 
binding assays were analyzed as described previously [22]. In short, association and 
dissociation rates of unlabeled ligands were calculated by fitting the data of the competition 
association assay using non-linear regression - kinetics of competitive binding [24] using 
equation 1.  
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Where k1 is the kon of the radioligand (M-1min-1), k2 is the koff  of the radioligand (min-1), L is 
the radioligand concentration (nM), I is the concentration of the unlabeled competitor (nM), X 
is the time (min) and Y is the specific binding of the radioligand (DPM). These parameters 
are set during a competition association, obtaining k1 from the control curve without 
competitor and k2 from previously performed dissociation assays described under 2.4 
Radioligand kinetic association and dissociation assays. With that the k3, k4 and Bmax can be 
calculated, where k3 represents the kon (M-1min-1) of the unlabeled ligand, k4 stands for the koff 
of the unlabeled ligand and Bmax equals the total binding (DPM). All competition association 
data were globally fitted. Data were normalized to maximal specific binding of 
[3H][Sar9,Met(O2)11]SP in absence of competitor. 
Data from xCELLigence experiments were exported from RTCA Software 1.2 (Roche, 
Germany) after normalizing the cell index (CI) traces to the time of agonist addition. Baseline 
was removed by subtracting vehicle or antagonist traces from corresponding normalized CI 
(NCI) traces. The maximal NCI response of each concentration (peak) was used for data 
analyses. 
Maximal response (Emax) and potency (pEC50) values for all agonists were analyzed 
with non-linear regression of peak analysis fitted by log(agonist) vs. response - Variable 
slope. Results were normalized to the maximal NCI response induced by SP. The peak of 
agonist-induced cellular responses in presence of antagonist were normalized to the peak 
obtained from treatment with submaximal concentrations of the corresponding agonist.  
Results 
Characterization of [3H][Sar9,Met(O2)11]SP  
The kinetic binding parameters of [3H][Sar9,Met(O2)11]SP interacting with CHOhNK1 
membranes were determined with traditional kinetic radioligand binding studies. Association 
and dissociation assays supplied kon and koff values of 0.17 ± 0.028 nM-1 min-1 and 0.016 ± 
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0.0015 min-1, respectively (Figure 2A and 2B). The kinetic KD (koff/kon) calculated from these 
experiments was 0.093 ± 0.018 nM. The dissociation constant was determined with 
homologous displacement experiments (Figure 2C) and yielded a KD of 2.5 ± 0.7 and this 
value was used to convert IC50 values to Ki values in the equilibrium binding studies.  
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Binding affinity of hNK1R peptide 
agonists  
The binding affinity of seven hNK1R 
peptide agonists was determined with 
equilibrium radioligand displacement 
studies. With the exception of NKB (no 
significant displacement at 10 µM, data not 
shown), all peptides were able to 
completely displace [3H][Sar9,Met(O2)11]SP 
in a concentration-dependent manner 
(Figure 3). Unlabeled Sar9,Met(O2)11-SP, 
SP, Pro9, hemokinin-1 and SP(4-11) all had 
nanomolar affinities, ranging from 2.1 nM 
for SP to 37 nM for SP(4-11). NKA and 
septide showed a much lower affinity in the 
micromolar range of 1933 nM and 2417 
nM, respectively (Table 1).  
Competition association assay 
optimization and validation with 
[3H][Sar9,Met(O2)11]SP  
The kon (k3) and koff  (k4) values of 
unlabeled Sar9,Met(O2)11-SP were 
quantified by fitting the kon (k1) and koff (k2) 
values of [3H][Sar9,Met(O2)11]SP into the 
model of ‘kinetics of competitive binding’ as 
described in Materials & Methods. Three 
different concentrations of  Sar9,Met(O2)11-
SP, i.e. 0.3-fold, 1-fold and 3-fold its IC50 
value, were tested and resulted in a shared kon (k3) and koff  (k4) value of 0.094 ± 0.011 nM-1 
min-1 and 0.026 ± 0.0029 min-1, respectively (Figure 4A and Table 1). The association and 
dissociation rates obtained with this assay agreed fairly well with those obtained in traditional 
binding assays (Table 1). Kinetic dissociation constants and affinity values were also in good 
agreement, validating the competition association as a valuable tool for the determination of 
binding kinetics of unlabeled hNK1 ligands. To improve the throughput of this assay it was 
examined if using a single concentration (i.e. 1-fold their IC50 value) yielded similar binding 
 
Figure 2: Association (A) and dissociation (B) 
kinetics of one concentration 
[3H][Sar9,Met(O2)11]SP (25 000 dpm, ~2.5 nM) 
and homologous displacement (C) of four 
concentrations [3H][Sar9,Met(O2)11]SP (i.e. 4 
nM, 3 nM, 2 nM and 1 nM) by 
[Sar9,Met(O2)11]SP on CHOhNK1 membranes 
at 4 °C. Representative graphs are shown 
from one experiment performed in duplicate. 
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kinetics parameters. The kon and koff 
values of the single concentration 
method proved to be not significantly 
different, i.e. 0.078  ± 0.012 nM-1 min-1 
and 0.024 ± 0.0038 min-1 respectively. 
Therefore, the remaining peptides were 
tested using this single concentration 
method.   
Binding kinetics of hNK1R peptide 
agonists 
The one-concentration 
competition association assay was 
used to determine the binding kinetics 
of the remaining agonists (Figure 4B 
and 4C). Ki values and kinetic KD 
values of all peptides were highly 
correlated (r2 = 0.99 and p<0.0001; data not shown), although kinetic KD values were around 
10-fold lower than Ki values.  Dissociation rates varied approximately 9-fold, ranging from 
0.026 ± 0.0029 min-1 for Sar9,Met(O2)11-SP and 0.21 ± 0.015 min-1 for septide (Table 1). 
Interestingly, a 240-fold difference was observed in association rates for the peptide 
agonists. SP had the fastest association rate of 0.24 ± 0.046 nM-1 min-1 and NKA showed the 
slowest association rate of 0.001 ± 0.0002 nM-1 min-1 (Table 1).  
NK1 receptor activation in human astrocytoma U-251 MG cells 
 
Figure 3: Displacement of one concentration 
[3H][Sar9,Met(O2)11]SP (25 000 dpm, ~2.5 nM) by 
NK1 peptide agonists on CHOhNK1 membranes 
at 4 °C. Representative graphs are shown from 
one experiment performed in duplicate (See Table 
1 for affinity values). 
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To examine receptor activation 
we used a cell line that endogenously 
expresses the human NK1 receptor, i.e. 
astrocytoma U-251 MG cells. 
Stimulation of the cells with agonist 
resulted in a rapid transient (~2 min) 
negative effect on the impedance 
followed by a positive response for all 
agonists (Figure 5A, representative trace 
of SP). Potency values (EC50) ranged 
from 0.04 ± 0.01 nM for  Sar9, Met(O2)11-
SP to 3.9 ± 1.8 nM for NKA while only 
NKA showed a significant increase in 
Emax in comparison to SP (Figure 5B, 5C 
and Table 1). Pre-incubation with 1 µM 
aprepitant, a selective non-peptide NK1 
receptor antagonist, completely 
abolished receptor signaling for all 
agonists (Figure 5D).  
Correlation plots of binding and 
receptor activation parameters of 
hNK1R peptide agonists 
Lastly, we investigated the 
correlation between the kinetic binding 
parameters (pkon and pkoff)  and the 
receptor activation parameters (pEC50 
and Emax). The dissociation rate 
constants correlated well with 
association rate constants (R2=0.73, 
P=0.014), potency (R2=0.67, P=0.025), 
maximal response values (R2=0.70, 
P=0.018) and a good correlation was 
obtained with affinity values (R2=0.84, 
P=0.0039). In contrast, the association rate constants did not show any significant correlation 
with the in vitro maximal response (R2=0.45, P=0.10).  Finally, an excellent correlation was 
 
Figure 4: Competition association assay at 4 °C 
with one concentration [3H][Sar9,Met(O2)11]SP (30 
000 dpm, ~3 nM) in the absence or presence of 
0.3, 1 or 3*IC50 value of unlabeled 
[Sar9,Met(O2)11]SP (A) or 1*IC50 value of SP (4-
11), septide and NKA (B) or SP, Pro9 and 
hemokinin-1 (C). Representative graphs are 
shown from one experiment performed in 
duplicate (See Table 1 for kinetic parameters). 
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observed between the association rate constants and the affinity (R2=0.99, P<0.0001) and 
potency values (R2=0.90, P=0.0012).  
Discussion 
Binding kinetics of endogenous tachykinins and their derivatives vary greatly 
Ligand-receptor binding kinetics are defined by the association and dissociation rates 
of a ligand to and from its receptor. These parameters are increasingly recognized to be 
important in the understanding of a drugs mechanism of action [5, 25, 26]. Many successful 
drugs achieve their effects by competing with endogenous ligands, therefore insights into the 
kinetics of endogenous ligands could provide clues for the desired binding kinetics of 
potential drugs. In this study we focused on determining the binding kinetics of endogenous 
tachykinins and their derivatives targeting the NK1 receptor, including but not limited to 
Substance P, NKA and hemokinin-1 (Figure 1) using a competition association assay. This 
assay was first described in 1984 [24] and has to date been used to investigate the binding 
kinetics of ligands for quite a number of GPCRs [22, 27, 28]. Here, we validated the 
competition association assay as a reliable method to determine the binding kinetics of 
unlabeled NK1 peptide agonists. This was demonstrated by the similar kon and koff values in 
comparison to the traditional association and dissociation assays, as well as the excellent 
correlation between the affinity and kinetic KD values. Notably, Ki values were consistently 
10-fold higher in comparison to kinetic KD values. It should be noted that there were some 
experimental differences between equilibrium displacement and competition association 
assays. For instance, equilibrium experiments were performed with 90 minutes incubation 
while the kinetic KD from the competition association is not (or less) time dependent. 
Moreover, to improve the assay window for competition association assays the concentration 
radioligand and membranes was increased. Additionally, membrane batches differed 
between assays. These differences can add up to the 10-fold discrepancy between 
equilibrium Ki and kinetic KD values reported in this study. Of note, literature Ki and KD values 
of NK1 agonists are also quite variable and even differ up to 20-fold [16, 29-31]. Investigation 
of the correlations between the kinetic binding parameters (kon and koff) and the affinity values 
of all agonists showed a significant correlation between pKi and pkoff values (R2=0.84, 
P<0.005) and an excellent correlation between pKi and pkon values (R2=0.99, P<0.0001). 
Since the association rate is often thought to be diffusion rate limited (108 ~ 109 M-1 s-1 [32]) 
and the affinity is calculated by dividing the dissociation rate by the association rate, it is 





between pKi and pkoff values are 
often reported [5, 25, 33], while a 
correlation between the 
association rate and affinity is 
less prevalent. However, in this 
study it was demonstrated that 
for the most well-known 
tachykinins the association rates 
ranged 240-fold while 
dissociation rates only differed 8-
fold. Takeda et al. also reported 
over 100-fold differences 
between the association rate of 
SP versus NKA while the 
dissociation rates only differed 3-
fold [34]. Similar to synthetic 
ligands for the β2-adrenoceptor, 
orexin-2 receptor and Kv11.1 
potassium channel [35-37], our 
findings illustrate that association 
rates are the main incentive that 
dictate the affinity of endogenous 
tachykinins targeting the NK1 
receptor. It should be noted that 
in addition to binding kinetics, 
other parameters such as 
rebinding, ligand elimination, 
degradation and target 
vulnerability also play an 
important role in the mechanism 





Figure 5: Concentration-dependent effects of NK1 
agonists on U-251 MG cells. Representative 
xCELLigence traces of one experiment performed in 
duplicate of normalized cell index (NCI) after stimulation 
with increasing concentrations of SP (A) and 
representative concentration-effect curves of all agonists 
derived from peak analysis, data were normalized to 
maximal response after SP stimulation (B and C). 
Representative bar graph of one experiment performed 
in duplicate of peak analysis after stimulation with EC80 
concentrations of agonist in presence or absence of 1 
μM aprepitant (D). 
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Diversity in NK1 receptor potency but not activation profiles on label-free impedance-
based system  
 In addition to the binding parameters we also investigated the receptor activation 
profiles of all tested tachykinins, except NKB. Most of the NK1 receptor signaling studies 
have been performed with G protein pathway-specific assays such as cAMP and IP turnover 
assays [14-16]. However, an assay that measures the whole cellular response over time 
overcomes the limitations of pathway-specific end-point assays and is thus more suitable to 
study NK1 receptor activation and its correlation to binding kinetics. Therefore we used a 
label-free impedance-based assay to study NK1 receptor activation in human astrocytoma U-
251 MG cells that endogenously express the NK1 receptor. Addition of increasing 
concentrations of agonist resulted in a concentration-dependent increase in impedance for all 
tested tachykinins. These responses were selectively inhibited by the small molecule 
antagonist aprepitant, supporting a NK1 receptor specific response. All tachykinins had much 
higher potencies in comparison to literature values that used endpoint assays [16, 39], which 
is often observed in label-free assays that monitor cell morphology rather than one 
downstream signaling pathway [40, 41]. Of note, the cell index trace was identical for fastly 
and slowly associating agonists. It could be argued that numerous factors are involved in 
receptor activation kinetics, such as the rate of G protein-coupling and kinetics of production 
of second messengers. These factors could prove it difficult to selectively measure the 
effects of agonist-receptor association rates on receptor activation kinetics.  
N-terminal domain of tachykinins is important for association rate and potency 
The N-terminus of tachykinins is believed to be important for receptor affinity and 
selectivity, albeit indirectly by regulating peptide conformations that are crucial in peptide-
receptor binding and activation [42, 43]. Valentin-Hansen et al. recently mapped SP binding 
sites on the NK1 receptor and reported that the first 6 C-terminal amino acids of SP are 
specifically organized fitting onto the surface of the receptor while the remaining N-terminal 
amino acids are forming a cone-shaped entity that could accommodate interactions with 
multiple residues of the N-terminal tail of the receptor [44]. Interestingly, in our study we 
found that tachykinins with shorter N-terminal domains such as NKA and septide not only 
had significantly reduced affinities and potencies but also had a more than 200-fold decrease 
in association rates (Table 1). It could be postulated that the slower association rates are due 
to a less optimal peptide conformation in consequence of a lack of interactions with the N-
terminal tail of the receptor resulting in a decreased affinity and potency. 
Binding kinetics correlate with in vitro activation profiles 
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A good correlation was observed between the dissociation rate and in vitro maximal 
response (Table 1). Correlations between in vitro maximal response and dissociation rates 
have been reported before. In example, Guo et al. [45] examined binding kinetics and 
efficacies of adenosine A2A agonists and found that slower dissociation correlated with 
increased efficacies in a label-free assay. Moreover, a study investigating dissociation rates 
and functional effects of muscarinic M3 receptor agonists proved that high maximal response 
values were positively correlated with slow dissociation rates [46]. Collectively, these findings 
support our observation that receptor dissociation rates can be a good predictor of in vitro 
efficacies at the NK1 receptor.  Moreover, a very good correlation was observed between the 
association rate and potency values. We found that tachykinins with faster dissociation rates 
and slower association rates (i.e. lower affinities) have lower potencies in comparison with 
SP. Interestingly, these agonists are known to only activate the Gαq pathway [16, 39, 47, 48]. 
A correlation between binding kinetics and biased signaling has been discussed before for 
the NK2 receptor. Specifically, an allosteric modulator for the NK2 receptor (i.e. LPI805), was 
investigated for its effects on the binding kinetics and signaling profile of NKA [14]. It was 
demonstrated that addition of LPI805 resulted in faster dissociation and slower association 
rates of NKA, as well as abolishing Gαs signaling.  
In conclusion, the competition association assay was validated as a valuable tool to 
study the binding kinetics of tachykinins targeting the NK1 receptor. We have, for the first 
time, elucidated the binding kinetics of endogenous tachykinins and their most well-known 
derivatives and found small differences in their dissociation rates (8-fold difference) and large 
differences in their association rates (240-fold difference). Dissociation rates correlated well 
with in vitro efficacies, while association rates correlated highly with potency values obtained 
with a label-free assay. Taken together, these results indicate that diverging binding kinetics 
can play a significant role in differentially activating the NK1 receptor. Our research 
underlines the importance of knowledge of binding kinetics of endogenous ligands, as it was 
demonstrated that for endogenous tachykinins both dissociation and association rate 
constants differed significantly which in turn had differential effects in receptor activation. 
Moreover, these kinetic values should be considered when designing novel competing drugs 





Table 1:  Binding (affinity, association rate and dissociation rate) and activation (in vitro potency and  
maximal response) parameters of  the examined tachykinins. 
Ligand pKi (and 
Ki in nM) 
pKD (and 







pEC50 # (and 
EC50 in nM) 
Emax 
(%)## 
Substance P 8.7 ± 0.01 
(2.1) 
10 ± 0.09 
(0.11) 





9.9 ± 0.1 
(0.07) 
100 ± 3 
Sar9, 
Met(O2)11-SP # 
8.5 ± 0.03 
(3.5) 









10 ± 0.1  
(0.04) 
110 ± 1 
Pro9 - SP 8.4 ± 0.02 
(3.8) 
9.5 ± 0.05 
(0.32) 





10 ± 0.08 
(0.06) 
116 ± 8 
Hemokinin-1 8.1 ± 0.08 
(8.1) 









10 ± 0.1  
(0.1) 
135 ± 22 
NKA 5.7 ± 0.04 
(1933) 












SP(4-11) 7.4 ± 0.04 
(37) 








9.9 ± 0.19 
(0.25) 
129 ± 10 
Septide 5.6 ± 0.03 
(2418) 








8.7 ± 0.06 
(1.8) 
134 ± 11 
Values are means ± SEM of three separate experiments performed in duplicate, #3-concentration 
competition association, # #Values were calculated with peak analysis and data were normalized to 
maximal response obtained for Substance P. Of note, NKB was unable to displace [3H]-Sar9, Met(O2)11-
SP (-3% and -10%  displacement at 10 µM). * p < 0.05, compared to Emax SP determined using one-
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An important question in drug discovery is how to overcome the serious challenge of 
high drug attrition rates due to lack of efficacy. A missing link in the understanding of 
determinants for drug efficacy is the relation between drug-target binding kinetics and signal 
transduction, particularly in the physiological context of (multiple) endogenous ligands. In this 
study we show, for the first time, how differences in drug-target binding kinetics lead to 
different cellular responses induced by endogenous agonists. Our findings were consistent 
throughout different kinetic assays and cellular backgrounds. We conclude that knowledge of 
the relationship between in vitro drug-target binding kinetics and cellular responses is 





Drug discovery is challenged 
with overcoming high attrition rates 
due to lack of efficacy in clinical trials. 
In the past decade, numerous 
researchers have proposed drug-
target binding kinetics (i.e. association 
and dissociation rates) as important in 
vitro parameters and have suggested 
including these early in the drug 
discovery paradigm [1-4]. While 
plasma pharmacokinetic profiles are 
relatively well understood, and 
progress is made in understanding 
and predicting target tissue distribution 
and target occupancy [5-7], the crucial 
step from drug-target binding kinetics 
to the in vivo cellular effects that 
precede the whole body’s response is 
typically missing (Figure 1). Since 
these responses cannot yet be 
measured in the living body, we have to use in vitro systems that reflect the in vivo conditions 
as closely as possible. So far numerous receptor binding assays, such as radioligand binding 
[8], surface plasmon resonance (SPR), surface acoustic wave (SAW) [9], and time-resolved 
fluorescence resonance energy transfer (TR-FRET) assays [10], have been designed and 
validated to study binding kinetics at the receptor level. However, there is a need for kinetic 
functional assays to better predict in vivo cellular responses of kinetically diverse 
compounds. Functional assays that are well suited for this purpose include the real-time 
GloSensor™ cAMP assay [11, 12], measuring cAMP production, and the real-time 
impedance-based xCELLigence™ assay [13, 14], that measures changes in cell morphology 
as a more integral cellular response.  
The neurokinin 1 (NK1) receptor is an example of a target for which drugs with 
optimal binding kinetics are reported. It is mainly expressed in the central nervous system 
(CNS) and plays a role in the regulation of affective behavior and emesis in the brain, as well 
as nociception in the spinal cord [15, 16]. While a plethora of NK1 antagonists have been 
synthesized [17-19], most antagonists have failed in the clinic due to a reported lack of 
efficacy [20, 21]. Currently, two small molecule NK1 antagonists are marketed to treat 
 
Supplemental Figure 1: Chemical structure of 
aprepitant (A) and desfluoro aprepitant (DFA) (B). 
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chemotherapy-induced emesis and nausea, namely aprepitant and netupitant. A study of 
Hale et al. indicated that aprepitant is superior to other NK1 receptor antagonists due to its 
slow receptor dissociation rate [22]. These results were confirmed in a later study in which 
the long-lasting in vivo effects of aprepitant were directly related to its slow dissociation rate 
rather than a long half-life [23]. More recently, the highly selective NK1 antagonist netupitant, 
in combination with a serotonin 5-HT3 receptor antagonist, was approved by the FDA [24]. 
Similar to aprepitant, netupitant’s effects were considered insurmountable, i.e. able to 
depress the maximal agonist-induced response by preventing agonist rebinding, and shown 
resistant to wash-out experiments, i.e. during wash-out netupitant was still tightly bound to 
the receptor [25]. The authors proposed slow receptor dissociation kinetics as the 
mechanism hereof.  
Another important aspect in in vivo receptor binding is competition of the drug with 
endogenous ligands. It is therefore crucial to study the binding kinetics and subsequent 
cellular responses of drug candidates in the presence of such endogenous ligands, as the 
binding kinetics of these competing endogenous ligands can be substantially different [26]. 
For example, the binding kinetics of endogenous NK1 receptor ligands, called tachykinins, 
such as substance P (SP) and neurokinin A (NKA) have been found to be very divergent 
[27]. The necessity of slow receptor binding kinetics of NK1 receptor antagonists to achieve 
high in vivo efficacy in addition to the varying binding kinetics of the endogenous tachykinins, 
i.e. NKA and SP, makes the NK1 receptor a good model system to examine distinct kinetic 
interactions of antagonist and agonist binding and their effects on signal transduction.  
In short, in this study the in vitro functional effects of receptor binding kinetics were 
examined for kinetically divergent agonists and antagonists using the NK1 receptor as a 
model system. We report differential signal transduction profiles for differential kinetic binding 
profiles of antagonists and endogenous agonists and these results were congruous 
throughout varying assay temperatures, cellular backgrounds and kinetic assays. Moreover, 
a novel approach studying the onset of receptor activation was designed. We provide, for the 
first time, a qualitative translation of binding kinetics into kinetic cellular responses enabling 





Reagents and compounds 
SP and NKA were purchased from Sigma-Aldrich (St. Louis, MO) and Bio-Connect 
(Huissen, The Netherlands), respectively. All NK1 antagonists were synthesized in-house as 
described previously[22]. Chinese Hamster Ovary (CHO) cells stably expressing the human 
neurokinin 1 receptor (CHOhNK1 cells) were kindly provided by AstraZeneca (Macclesfield, 
UK) and U-251 MG cells were purchased from Sigma-Aldrich (St. Louis, MO). xCELLigence 
E-plate 16 and 96 were purchased from Westburg (Leusden, the Netherlands). 
pGloSensor™-22F cAMP plasmid, GloSensor™ cAMP reagent and FuGENE HD 
transfection reagent were obtained from Promega GmbH (Mannheim, Germany). 
CELLSTAR® 384-Well Plates, Tissue Culture Treated were purchased from Greiner Bio-One 
(Frickenhausen, Germany). [3H][Sar9,Met(O2)11]SP (specific activity 25-55 Ci/mmol) was 
obtained from Perkin Elmer (Boston, MA). All other reagents and materials were obtained 
from commercial resources.  
Cell culture 
 
Figure 1: Schematic overview of factors involved between drug dosing and body responses, 
i.e. drug effects. While drug dosing, plasma pharmacokinetics, target tissue distribution, intra-
tissue or target site distribution, cellular signal transduction and body responses are often 
examined drug-target binding kinetics are often disregarded. More importantly, elucidation of 
the pivotal step, i.e. effects of binding kinetics on signal  transduction, from drug-target 
binding kinetics to in vivo drug responses is highly desirable. 
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U-251 MG cells were cultured in Earle’s Minimal Essential Medium (EMEM) 
supplemented with 10% FCS, 1 mM sodium pyruvate, 2 mM glutamine, 1% non-essential 
amino acids (NEAA), 100 IU/ml penicillin and 100 µg/ml streptomycin at 37 °C + 5% CO2. 
CHOhNK1 cells were cultured in Ham’s F12 medium supplemented with 10% fetal calf 
serum (FCS), 2 mM glutamine and 1 mg/ml G418 at 37 °C + 5% CO2.  
Dual-point competition association assays 
 Dual-point competition association assays were performed as prescribed previously 
[28], following the radioligand binding protocol of Nederpelt et al.[27]. In short, CHOhNK1 
membrane aliquots containing 5-15 µg protein were incubated at 4 °C with 25 000 dpm (~2.5 
nM) [3H][Sar9,Met(O2)11]SP and one concentration of competing antagonist (i.e. concentration 
at which approximately 50% (30-70%) [3H][Sar9,Met(O2)11]SP binding was achieved). Specific 
binding of [3H][Sar9,Met(O2)11]SP was determined at two time-points; 30 min (t1), which is the 
time-point at which equilibrium of [3H][Sar9,Met(O2)11]SP binding was achieved, and 120 min 
(t2) at which all competing antagonists reached equilibrium.  
Impedance-based morphology assays 
Label-free morphology assays were performed using the xCELLigence RTCA system 
as described previously [27, 29]. U-251 MG cells were treated with three different 
concentrations (0.07 nM, 0.21 nM and 0.7 nM) of aprepitant or DFA for 30 min prior to 
stimulation with increasing concentrations of SP or NKA.  
Real-time cAMP accumulation assay  
Real-time cAMP production was measured using the life cell cAMP GloSensorTM 
assay [11, 12]. The technology is based on a cAMP-biosensor, which undergoes a 
conformational change upon cAMP binding, followed by the turnover of Luciferin.  
CHOhNK1 cells were transiently transfected with the pGloSensor™-22F cAMP (i.e. 6 
ng/µL) plasmid using FuGene HD (3 µL:1 µg DNA plasmid) as a transfection reagent. 
Accordingly, cells were harvested and reconstituted to 0.5 x 106 cells/ml (10.000 cells/well) in 
DMEM/F-12/ HEPES supplemented with 1% FCS, 2 mM glutamine and 1 mg/ml G418. The 
diluted plasmid solution was combined with the transfection reagent and incubated for 20 min 
at room temperature. Subsequently, the transfection mixture and cell solution were mixed for 
additional 5 min before plating in 384-well plates. The transfected cells were incubated for 24 
h at 37 °C + 5 % CO2 followed by treatment with Glo-substrate (i.e. 3% v/v) for 2 h at room 
temperature. Subsequently, three different concentrations (0.07 nM, 0.21 nM and 0.7 nM) of 
Aprepitant or DFA were added to cells for 30 min (pre-incubation) using Echo™ 550 Liquid 
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Handler (Labcyte), followed by addition of increasing concentrations of SP or NKA. Real-time 
changes in the level of cAMP were detected using an Envision HTS microplate reader 2103 
(PerkinElmer).  
Data analysis 
All experimental data were analyzed using the curve-fitting program GraphPad Prism 
v. 6.00 (GraphPad Software Inc., San Diego, CA).  
Data from dual-point competition association assays were analyzed by dividing the 
specific binding at t1 (Bt1) with the specific binding at t2 (Bt2).  
KRI = Bt1 / Bt2 
Data from morphology and cAMP experiments were analyzed as described previously 
[27]. Efficacy (Emax) and potency (pEC50) values for SP and NKA were analyzed with non-
linear regression of peak analysis fitted by log(agonist) vs. response - Variable slope. Results 
were normalized to the maximal response induced by agonist without antagonist.  
The onset of receptor activation was analyzed by calculating the slope with linear 
regression of the first 8 minutes of the cellular response.   




All data are means of at least three separate experiments performed in duplicate or 
triplicate. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-test.  
Results  
Aprepitant and DFA have very divergent binding kinetics at the NK1 receptor 
 The kinetic binding parameters of 87 small molecule NK1 receptor antagonists were 
determined using a qualitative kinetic screening method, namely a dual-point competition 
association assay (data not shown). These experiments yielded KRI values ranging from 0.7 
± 0.18, to 2.0 ± 0.18, i.e. indicating faster and slower dissociation kinetics in comparison to 
the radioligand [3H][Sar9,Met(O2)11]SP, respectively. Aprepitant (KRI of 1.8 ± 0.10) and DFA 
(KRI of 1.0 ± 0.13) were selected for further studies as they had the highest chemical 




Figure 2: Real-time NK1 receptor-mediated responses monitored with cAMP (A and B) or 
morphology (C and D) experiments induced by addition of increasing concentrations of 
endogenous agonist SP (A and C) or NKA (B and D). Representative graph of at least three 
experiments performed in duplicate (morphology assays) or triplicate (cAMP assays). RLU 
stands for relative light units and NCI stands for normalized cell index. 
Real-time functional effects of NK1 receptor activation by SP and NKA are 
comparable between kinetic assays  
The cellular response to NK1 receptor activation was monitored using two real-time 
assays, namely a cAMP assay (GloSensor) and a morphology-based assay (xCELLigence). 
A time-dependent and concentration-dependent increase in cAMP production was observed 
with the GloSensor assay for both endogenous agonists SP and NKA with a maximal cAMP 
value around 20 to 30 minutes after stimulation (Figure 2A and B). These experiments 
yielded EC50 values for SP and NKA of 2.2 ± 0.5 nM and 483 ± 142 nM, respectively (Table 1 
and 2). Similarly, upon SP or NKA stimulation cellular impedance was increased time- and 
concentration-dependently with a peak response around 20-30 minutes (Figure 2C and D), 
with EC50 values of 0.026 ± 0.004 nM for SP and 3.9 ± 1.1 nM for NKA (Table 1). Potencies 





Figure 3: Concentration-dependent effects induced by endogenous agonist SP pre-
incubated with vehicle (control), DFA or aprepitant determined with cAMP (A and B) or 
morphology (C and D) experiments. Concentration-dependent effects induced by 
endogenous agonist NKA pre-incubated with vehicle (control) DFA or aprepitant determined 
with cAMP (E and F) or morphology (G and H) experiments. Representative graph of at least 
three experiments performed in duplicate (morphology assays) or triplicate (cAMP assays). 
RLU stands for relative light units and NCI stands for normalized cell index. 
 
Aprepitant is more effective in decreasing SP-mediated maximal response  
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To investigate the antagonistic effects of aprepitant and DFA on SP-mediated NK1 
receptor activation, cells were pre-incubated with varying concentrations of antagonist prior 
to stimulation with SP. In the cAMP assay both antagonists were unable to significantly shift 
the EC50 of SP, however the Emax of SP was significantly decreased (Figure 3A and B, Table 
1). At the highest concentrations aprepitant was more efficacious in lowering the Emax than 
DFA abolishing over 80% in comparison to control while DFA only decreased the Emax by 
39% (Table 1). Interestingly, in the morphology assay both antagonists increased the EC50 
values of SP to 3.0 ± 1.3 nM for DFA and 0.23 ± 0.08 nM for aprepitant (Figure 3C and D, 
Table 1). Similar to the cAMP assay, the Emax of SP was significantly reduced by the 
antagonists to 82 ± 6.9% of control in the presence of DFA and to a larger extent for 
aprepitant, i.e. to 53 ± 8.5% (Table 1). Moreover, IC50 values were examined by pre-
incubating increasing concentrations of antagonist prior to addition of EC80 concentrations of 
agonist (Figure 4). This resulted in IC50 values of 0.15 ± 0.02 nM (cAMP assay) and 0.22 ± 
0.1 nM (morphology assay) for DFA. IC50 values for aprepitant were comparable to DFA with 
0.19 ± 0.07 nM and 0.58 ± 0.22 nM from the cAMP and morphology assay, respectively.   
Antagonistic effects were more pronounced upon NKA-mediated receptor activation 
The inhibitory effects of both antagonists were also investigated for NKA-mediated 
NK1 receptor activation. In the cAMP assay, aprepitant was able to decrease the potency of 
NKA by 10-fold, while DFA did not affect the agonist potency (Figure 3E and F, Table 1). 
This is markedly different from the results observed with SP-mediated receptor activation. 
Conversely, both antagonists lowered the maximal effect of NKA, while aprepitant was most 
effective and lowered the Emax to 7.8 ± 4.2% (Table 1). On the xCELLigence, the highest 
concentrations of both antagonists increased the EC50 values by 2-fold for DFA and 7-fold for 
aprepitant (Figure 3G and H, Table 1). Similar to the cAMP assay, both antagonists 
decreased the maximal effect of NKA while aprepitant was more efficacious (30 ± 6.2%) than 
DFA (81 ± 8.9%) (Table 1). Furthermore, pretreatment of increasing concentrations of 
antagonist prior to addition of EC80 concentrations of agonist resulted in IC50 values ranging 
from 0.26 ± 0.08 nM (cAMP) to 0.12 ± 0.006 nM (morphology) for DFA while IC50 values for 
aprepitant ranged from 0.23 ± 0.09 nM (cAMP) to 0.43 ± 0.07 nM (morphology) (Figure 4). 
IC50 values of aprepitant and DFA obtained from the two assays were similar.  
Aprepitant caused a reduced rate of NK1 receptor activation induced by NKA and SP   
 To examine the real-time effects of DFA and aprepitant on the inhibition of the cellular 
response to NK1 receptor activation, a novel analysis method was designed to examine the 
onset of receptor activation. The increase in cAMP production within the first 8 minutes after 
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addition of the endogenous agonist was compared in the presence and absence (control) of 
an antagonist. The onset of SP-induced cAMP production was significantly decreased (i.e. 
up to 6-fold) upon pre-incubation with aprepitant but not with DFA (Figure 5A, B and C, Table 
2). Similarly, the onset of SP-induced impedance changes was significantly decreased 5-fold 
upon aprepitant pretreatment, while pretreatment with DFA was less significant (Figure 5D 
and E, Table 2). Moreover, the ability of aprepitant to reduce the onset of receptor activation 
was more pronounced for NKA, where a significant 15-fold decrease in onset was observed 
in cAMP production and a significant 8-fold decrease for morphological changes (Figure 6F, 
G, H and I Table 2). Conversely, DFA did not significantly decrease the onset of receptor 
activation in both cAMP and morphology assays.  
 
Figure 4: Concentration-dependent inhibition by DFA or aprepitant of EC80 concentrations 
of SP- or NKA- mediated receptor activation measured with morphology (A) or cAMP (B) 
experiments. Representative graph of at least three experiments performed in duplicate 
(morphology assays) or triplicate (cAMP assays). RLU stands for relative light units and NCI 
stands for normalized cell index. 
 
Discussion  
 To our knowledge, we are the first to provide an extensive investigation on in vitro 
cellular responses in relation to receptor binding kinetics of antagonists and endogenous 
agonists. This research has significant implications for the understanding of signal 
transduction induced by kinetically diverse ligand-receptor interactions and the interplay 
between endogenous agonists and drugs targeting the receptor of interest.  
The NK1 receptor is an interesting target for the treatment of neurological disorders 
and currently two drugs, aprepitant and netupitant, are approved for the treatment of 
chemotherapy induced emesis [30]. While the high in vivo efficacy of aprepitant is attributed 
to its slow dissociation kinetics [23], a mechanistic interpretation of the translation of binding 
kinetics to functional effects is lacking. Therefore, this study was designed to bridge the gap 
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between receptor binding kinetics and functional effects in vitro, which is important for the 
understanding of the translation of in vitro to in vivo data.  
We hypothesized that the slowly dissociating antagonist aprepitant would be more 
effective in antagonizing the receptor than its fast dissociating analogue DFA. The rightward-
shift in potency of SP and NKA was most discernable at the highest concentration of 
antagonist, where aprepitant increased the EC50 value and decreased the Emax value more 
significantly than DFA (Table 1, Figure 3). While aprepitant was fully insurmountable, DFA 
was only partially insurmountable. The latter can be explained by the fact that although DFA 
is a faster dissociating compound when compared to aprepitant, DFA is still a slower 
dissociating compound in comparison to the endogenous agonists SP and NKA. Hence, pre-
incubation with DFA resulted in partially insurmountable antagonism as opposed to 
surmountable antagonism with an even faster dissociating antagonist. Our results for 
aprepitant are in line with its previously reported insurmountable effects [22]. In the same 
study the ID50 values of aprepitant and DFA were determined in an animal model for CNS 
activity (gerbil foot tapping), where aprepitant was 3-fold more potent than its analogue DFA 
[22]. Another study examined the insurmountable effects of a close analogue of aprepitant 
and DFA, namely L-742,694. A clear decrease in Emax of SP after pre-incubation with L-
742,694 was reported and this effect was associated with the slow dissociation rate of this 
antagonist from the NK1 receptor [31]. Altogether, these findings support our hypothesis that 
slowly dissociating antagonists are important for achieving a high in vivo efficacy by 
insurmountable antagonism at the NK1 receptor.  
While both antagonists aprepitant and DFA were able to increase the EC50 and 
decrease Emax values for both NKA and SP, NKA was overall more sensitive to antagonism 
than SP. This supposed “probe-dependency”, i.e. observed effects are dependent on the 
probe (e.g. agonist) used, is already widely acknowledged in the field of allosteric modulation 
[32, 33], while this concept is rarely considered for orthosteric interactions. Interestingly, we 
have previously determined the binding kinetics of SP and NKA and found large differences 
in the association rates of both agonists, i.e. NKA associates 240-fold slower to the NK1 
receptor than SP [27]. This slow association could be an explanation as to why NKA is more 
sensitive to antagonism, considering that both antagonists have more time to intervene with 
NKA target binding due to their assumed faster association rates, slower dissociation rates 
and pre-incubation time. The differential kinetics (and therefore sensitivity) of both 
endogenous agonists should be taken into account for further research towards the NK1 
receptor and other GPCRs that have multiple endogenous ligands [26].  
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A comparison between EC50 values obtained with the cAMP or morphology assays 
showed lower potency values for the latter. This is in line with other observations, namely 
that potency values acquired from label-free assays such as the xCELLigence are often 
reported to be much lower and may be attributed to the fact that these assays encompass 
the entire cellular response thereby accumulating multiple signaling pathways instead of only 
one [34-36]. Moreover, it appeared that the morphology assay was more sensitive to pick up 
shifts in potency upon antagonist treatment while the cAMP assay was most sensitive in 
detecting insurmountability, i.e. a decrease in maximal effect. A possible explanation could 
be the differences in assay set-up that can alter the assay sensitivity. For instance, 
morphology experiments are typically performed at 37 °C while cAMP assays were carried 
out at 25 °C. Lower assay temperatures result in slower dissociation rates which could 
explain the higher sensitivity of the cAMP assay to detect insurmountability. Moreover, the 
cAMP assay was carried out with CHOhNK1 cells while the morphology assay was 
performed with U-251 MG cells. Multiple studies have previously discussed the concept of 
receptor reserve, i.e. high receptor coupling efficiency and/or high-receptor density [37, 38]. It 
was proposed that tissue with essentially no receptor reserve treated with an insurmountable 
antagonist could present a decrease in maximal response with only a marginal rightward shift 
in potency. Heterologous cell lines are often reported to have higher receptor reserves in 
comparison to cell lines with endogenous expressions. Our results suggest that U-251 MG 
cells may have a higher receptor reserve than CHOhNK1 cells and U-251 MG cells might 
therefore be better suited to detect a shift in potency. These findings demonstrate the 
importance of choosing the appropriate assay and cell type for the aim of the research.   
The functional effects of antagonist binding kinetics are often examined with 
insurmountability assays using end-point measurements [39] but also real-time experiments 
[40]. Although a few studies have paid some attention to the real-time changes in cellular 
effects [13, 14, 41, 42], we are the first to report a quantitative analysis method for the real-
time cellular responses induced by agonists with antagonist pre-incubations. In this study, we 
were able to correlate the kinetics of receptor activation (i.e. rate of onset) to receptor binding 
kinetics of antagonists. The slowly dissociating antagonist aprepitant was effective in not only 
significantly decreasing the maximal effect of SP and NKA but also in significantly reducing 
the onset of receptor activation, which would have been missed using a traditional end-point 
assay. Hence, this novel analysis provides a robust and time-efficient screening method to 
detect slowly dissociating antagonists using a real-time functional assay.  
In conclusion, in this research the effects of kinetically diverse agonists and 
antagonists on receptor responses were extensively studied. We demonstrated that the 
binding kinetics of both antagonists and endogenous agonists have significantly different 
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effects on signal transduction profiles, i.e. potency values, in vitro efficacy values and onset 
rate of signal transduction. Moreover, these findings were consistent throughout different 
kinetic assays, assay temperatures and cellular backgrounds. We propose that incorporating 
real-time functional assays early in the drug discovery program will enable the detection of 
kinetically interesting compounds. Moreover, combining knowledge of binding kinetics and 
functional kinetics of drugs and endogenous ligands could improve predictions of in vivo drug 





Figure 5: Time-dependent effects induced by EC80 concentration of SP after pre-incubation with DFA 
or aprepitant observed with cAMP assay (A). Zoom-in on first 8 minutes of time-dependent effects 
induced by EC80 concentration of SP (B and C) or NKA (F and G) after pre-incubation with DFA or 
aprepitant determined with cAMP experiments. Representative graph of at least three experiments 
performed in triplicate. RLU stands for relative light units. Zoom-in on first 8 minutes of time-
dependent effects induced by EC80 concentration of SP (D and E) or NKA (H and I) after pre-
incubation with DFA or aprepitant determined with morphology experiments. Representative graph of 




Table 1: Potency and maximal effect values of SP with or without antagonist pre-incubation determined with cAMP or morphology assays 
 EC50  (nM) Emax (%) 
 cAMP morphology cAMP morphology 
 SP NKA SP NKA SP NKA SP NKA 
Agonist 2.2 ± 0.5 483 ± 142  0.026 ± 0.004 3.9 ± 1.1  100 ± 5.1 100 ± 7.7 100 ± 0.95 100 ± 0.44 
+ 0.07 nM DFA 1.9 ± 0.5 NS 399 ± 19 NS 0.053 ± 0.020NS 3.0 ± 0.52 NS 78 ± 4.5* 84 ± 18 NS 97 ± 5.6 NS 109 ± 7.6 NS 
+ 0.21 nM DFA 2.7 ± 0.8 NS 304 ± 89 NS 0.06 ± 0.015* 3.3 ± 0.45 NS 75 ± 7.7* 67 ± 10*  104 ± 4.2NS 108 ± 6.7 NS 
+ 0.7 nM DFA 2.3 ± 0.7 NS 1080 ± 356 NS 3.0 ± 1.3* 8.5 ± 0.46* 61 ± 10** 61 ± 15*  82 ± 6.9** 81 ± 8.9** 
+ 0.07 nM aprepitant 1.6 ± 0.2 NS 1008 ± 165 NS  0.022 ± 0.008NS 5.0 ± 1.7 NS 62 ± 5.7** 71 ± 13 NS 96 ± 7.6NS 97 ± 2.3NS 
+ 0.21 nM aprepitant 8.8 + 5.4 NS 1051 ± 170*   0.11 ± 0.01**** 8.0 ± 2.8 NS 55 ± 15** 43 ± 19** 79 ± 5.0*** 79 ± 10** 
+ 0.7 nM aprepitant  1.3 ± 0.3 NS 4370 ± 524*** 0.23 ± 0.08** 26 ± 6.8** 19 ± 5.5**** 7.8 ± 4.2**** 53 ± 8.5**** 30 ± 6.2**** 
Values are means ± SEM of at least three separate experiments performed in duplicate (morphology) or triplicate (cAMP). Values were calculated with peak 
analysis and data were normalized to maximal response obtained for SP or NKA only. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to SP or 




Table 2: Onset of SP- or NKA-induced receptor activation after pretreatment with DFA or aprepitant determined with 
cAMP or morphology assays.  
 cAMP (RLU min-1)# Morphology (NCI min-1) # 
 SP NKA SP NKA 
Agonist 215 ± 37 147 ± 35 0.05 ± 0.004 0.05 ± 0.004 
+ 0.07 nM DFA 125 ± 31NS 98 ± 29NS 0.06 ± 0.006NS 0.06 ± 0.005NS 
+ 0.21 nM DFA 120 ± 27NS 98 ± 33NS  0.05 ± 0.006NS 0.05 ± 0.007NS 
+ 0.7 nM DFA 158 ± 26NS 71 ± 22NS 0.03 ± 0.005* 0.04 ± 0.014NS 
+ 0.07 nM aprepitant 94 ± 13* 75 ± 13NS 0.05 ± 0.002NS 0.05 ± 0.011NS 
+ 0.21 nM aprepitant 63 ± 17** 43 ± 7.7* 0.04 ± 0.006NS 0.03 ± 0.007NS 
+ 0.7 nM aprepitant  36 ± 7** 9.7 ± 1.6** 0.009 ± 0.003**** 0.006 ± 0.003**  
Values are means ± SEM of at least three separate experiments performed in duplicates (morphology) or triplicates 
(cAMP). The onset of receptor activation was calculated on the first 8 min after agonist stimulation. # RLU stands for 
relative light units and NCI stands for normalized cell index. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
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Chapter 7  





In this thesis the binding kinetics of endogenous neuropeptides and drugs targeting 
two well-known neuropeptide receptors (i.e. the GnRH receptor and NK1 receptor) have 
been investigated. Kinetic binding and functional assays have been designed and validated 
to examine the differences in binding kinetics of the above-mentioned ligands. This final 
chapter focusses on providing a conclusion to the previous chapters while highlighting 
ongoing challenges with regard to binding kinetics. Moreover, opportunities for further 




Kinetic assays contribute to a more complete pharmacological profile of ligands  
 Assays applied in current drug discovery are mainly used for equilibrium assessments 
of drug candidates. However, since kinetic binding parameters are increasingly recognized 
as important considerations in drug discovery a need for kinetic assays is imminent. 
Throughout all the chapters of this thesis, several binding and functional assays have been 
designed to serve kinetic binding assessments of various ligands. In Chapter 3 kinetic 
radioligand binding studies were compared to kinetic time-resolved fluorescence resonance 
energy transfer (TR-FRET) studies. For both assays a competition association assay was 
developed and validated and results obtained from the two methods were highly correlated. 
In Chapter 4 a functional wash-out experiment using the label-free real-time xCELLigence 
was performed with the two most kinetically diverse agonists from Chapter 3. The results 
from these experiments were in agreement with the kinetic data obtained with the kinetic 
radioligand and TR-FRET binding assays. Moreover, in Chapter 6 a medium-throughput 
kinetic screening assay was used to qualitatively examine the dissociation rates of a library 
of antagonists. Two exemplary antagonists with contrasting dissociation rates were further 
examined with two kinetic functional assays. Kinetic functional data from a real-time 
impedance-based morphology assay and a novel real-time cAMP assay corresponded well 
with the kinetic screening assay. Furthermore, data from both kinetic functional assays were 
highly correlated. In conclusion, kinetic binding and kinetic functional assays are very 
suitable and transferable for the investigation of kinetic ligand-receptor interactions.  
Binding kinetics of endogenous neuropeptides are very diverse 
 Neuropeptides are 3-100 amino acid long polypeptides and are synthesized by 
neurons. They can bind neuropeptide receptors and together they are involved in many 
physiological and behavioral functions, making neuropeptides and their cognate receptors an 
attractive target to treat a wide range of diseases. While drug discovery programs 
predominantly focus on characterizing the drug candidate, knowledge of the pharmacological 
profile of the endogenous ligand and its target is essential when orthosteric drugs are 
desired. Chapter 2 reviews the kinetic profile of three exemplary neuropeptide receptors and 
their endogenous ligands (i.e. GnRH receptor, CRF1 receptor and NPY receptor). The 
neuropeptide binding kinetics, release rate and receptor internalization rates were very 
different for all three receptor-neuropeptide pairs emphasizing the importance and variability 
of kinetic profiles. Moreover, in Chapter 5 the binding kinetics of multiple endogenous ligands 
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targeting the NK1 receptor were determined. These ligands proved to have very different 
binding kinetics, particularly association rates were very variable.  
Differential binding kinetics can have differential functional effects in vitro  
While binding kinetics are progressively acknowledged as pivotal pharmacological 
parameters of a drug candidate, understanding of the translation of binding kinetics to in vitro 
and in vivo functional effects is still largely absent. The in vitro functional effects of 
neuropeptide agonists with variable dissociation rates were examined in Chapter 4. Long 
lasting receptor activation was evident for a slowly dissociating agonist while a fastly 
dissociating analog failed to show persistent receptor activation. Additionally, Chapter 5 
demonstrated that differences in association rates lead to altered potency and efficacy 
values in vitro. Moreover, differential binding kinetics of endogenous ligands and their 
competing antagonists play an important role in the interaction of the ligands with the 
receptor. In Chapter 6, it was illustrated that slowly dissociating antagonists can have 
superior efficacy to its fastly dissociating counterpart. Additionally, slowly dissociating 
antagonists can cause a reduced rate of signal transduction. Moreover, the binding kinetics 
of the competing endogenous ligands also proved to be of importance. Antagonistic effects 
were significantly bigger in the presence of a slowly associating in comparison to a fastly 
associating endogenous ligand.         
In summary, this thesis provides a large variety of kinetic assays that can be used to 
qualitatively and quantitatively determine receptor binding kinetics of ligands of interest. 
Additionally, the binding kinetics of endogenous neuropeptides can be very different and 
should therefore be considered when designing orthosteric drugs. Moreover, the combination 
of endogenous ligands and competitive drugs with differential binding kinetics can have 
significantly different functional effects in vitro. Finally, a wide range of kinetic assays, 
improved knowledge of endogenous ligand binding kinetics and a good understanding of the 
translational effects of binding kinetics could improve drug discovery today and decrease 
drug attrition rates in the future.  
Lessons learned 
Assay considerations  
 The search for optimal assay conditions is particularly challenging when designing an 
assay to study binding kinetics for neuropeptide ligands. Firstly, kinetic binding assays that 
utilize a tracer ligand are heavily reliant on the binding kinetics of the tracer. If the aim of the 
project is to find slowly dissociating ligands and the binding kinetics of tracer are very fast, 
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the mathematical model to evaluate the results is unable to provide quantitative data. To 
acquire quantitative parameters, the binding kinetics of the tracer ligands and unlabeled 
ligands should ideally be in the same time range (i.e. seconds, minutes, hours). Secondly, 
kinetic binding assays are often carried out at room temperature or sometimes at even lower 
temperatures. In these cases, the obtained kinetic binding parameters are not measured at 
physiological temperature (37 °C). It should be taken into account that binding kinetics will be 
significantly faster at higher temperatures [1-3]. Lastly, the type of kinetic assay can also be 
of influence. For instance, functional assays are often implemented as endpoint 
measurements, e.g. accumulation of a protein or 2nd messenger measured after a certain 
incubation time. Consequently an over- or underestimation of pharmacological parameters 
can occur due to inadequate incubation times. Conversion of endpoint assays into real-time 
measurements could circumvent this limitation.  
Pharmacological profile of the drug, receptor and its endogenous ligands in the 
human body 
 The need for fast or slow binding kinetics of a drug candidate is always relative to its 
target system and therefore understanding of the pharmacological profile of the entire system 
is crucial. Firstly, the pharmacokinetic (PK) half-life of the drug candidate needs to be 
considered. For example, if the PK half-life is slower than the residence time (RT) of the drug 
the latter becomes less relevant. Conversely, if the RT of the drug is slower than the PK half-
life, binding kinetics play a pivotal role in dictating the duration of action of the drug, 
assuming target engagement in vivo. Secondly, the internalization and desensitization rate of 
the targeted receptor should be taken into account. For instance, if the internalization rate of 
the receptor is faster than the dissociation rate of the drug the latter becomes trivial for 
agonist (and arguably antagonist) drugs. Correspondingly, if the receptor internalizes slowly, 
binding kinetics of agonist (and arguably antagonist) drugs can be very pertinent as the drug 
effect is hardly limited by receptor internalization. Finally, the kinetic profiles of both the drug 
and the endogenous ligands should be deliberated. Since the majority of drugs target the 
orthosteric binding site of the receptor, they are in constant competition with endogenous 
ligands. Concentrations of endogenous ligands in the human body often fluctuate 
significantly and binding kinetics can also be quite variable. Consequently, the binding 
kinetics and release rate of endogenous ligands should be determined in anticipation of 
achieving optimal binding kinetics of the drug candidate.  
Future perspectives  
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 This thesis predominantly focused on binding kinetics, ranging from designing and 
comparing kinetic assays to determining kinetic parameters of well-known drugs and 
endogenous ligands and translating binding kinetics to in vitro functional effects. The 
following paragraphs will discuss some future perspectives for neuropeptide receptors and 
GPCRs in general.  
Increasing the output of kinetic assays  
 Within this thesis we have discussed multiple assays suitable for qualitative and 
quantitative measurements of ligand-receptor binding kinetics. Additional, more high-
throughput screening methods could aid in the applicability of kinetic assays in drug 
discovery programs. Guo et al. have developed a medium-throughput screening assay to 
qualitatively estimate dissociation rates of ligands [4]. To date this screening assay has been 
successfully applied to multiple GPCRs [5-7], including the NK1 receptor in this thesis. 
However, a screening assay suitable for the estimation of association rates is still lacking. 
Additionally, while some binding assays can be transformed in high-throughput formats, 
radioligand binding assays are often performed in very low throughput formats. Glickman et 
al have reviewed the potential of using scintillation proximity assays (SPA) in high-throughput 
screening and kinetic measurements [8]. To date only a few research groups have used this 
SPA assay to study binding kinetics of GPCR ligands. In 2007, the kinetics of small molecule 
GnRH antagonists were qualitatively assessed in a high-throughput format [9] and more 
recently, a quantitative determination of the binding kinetics of human adenosine A1 receptor 
ligands was reported [10]. 
When researchers are interested in examining binding kinetics of antagonists in 
functional assays, insurmountability assays are typically the assay of choice. However, this 
assay is heavily reliant on assay conditions. For instance, a recent study of Vauquelin et al 
demonstrated the importance of pre-incubation times, where too short a pre-incubation of 
antagonist might not be sufficient for decreasing the maximal response [11]. Importantly, ‘’too 
short’’ pre-incubation times are dependent on the association rate of the antagonist and 
assay temperatures and might therefore be different per ligand and assay. Moreover, the 
time at which measurements are terminated could result in skewed results depending on the 
equilibrium between receptor, agonist and antagonist. Additionally, the kinetic data from 
functional assays such as the real-time cAMP assay and the real-time impedance-based 
morphology assay are often disregarded, as results from only one time-point are considered. 
Chapters 4 and 6 demonstrate the value of acknowledging functional kinetics and further 
studies of this concept on other targets would be beneficial. 
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Beyond binding kinetics, what happens after a ligand binds to its target? 
Throughout the chapters in this thesis the in vitro translational effects of binding kinetics 
have been explored, including the kinetics of cellular responses. To gain more insights into 
these receptor activation kinetics more information should be gathered about the individual 
kinetics of all proteins and enzymes involved in the final response. To illustrate the kinetic 
information available to date, the kinetics of the Gαq pathway are reviewed here (Figure 1). 
The Gαq pathway is initiated by binding of an agonist to the Gαq coupled receptor leading to a 
conformational change which results in the exchange of GDP for GTP and activation of the G 
protein. Consequently, phospholipase C (PLC) is activated and induces hydrolysis of 
phosphoinositol 4,5-biphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3). IP3 subsequently 
binds to IP3 receptors resulting in the release of Ca2+ into the cytosol, which induces the 
activation of myosin light chain kinases (MLCKs). Finally, upon activation of MLCKs actin 
filaments are contracted. All these processes together occur within seconds but information 
on the kinetic parameters of components of the Gαq pathway is limited and the 
representation is not consistent throughout the literature (e.g. rate constants versus time  
constants). It should be noted that these (rare) reports of kinetics of the activation and 
production of these downstream proteins could be receptor and pathway specific. For 
instance, G protein coupling and activation could be different for all G protein subtypes, i.e. 
Gαs protein coupling being faster or slower than Gαq coupling. Another important factor to 
consider is the kinetic differences in G protein and β-arrestin coupling. A study of Nuber et 
al., reported a tau value (time constant) of 2.2 s for β-arrestin coupling to the β2-adrenergic 
receptor [12], versus 0.05-25 s for G protein coupling. Arguably, the GPCR under 
investigation could also influence the kinetics of G protein coupling. Moreover, it should be 
noted that ligand-receptor binding kinetics could influence the rate of G protein or β-arrestin 
coupling and activation.  
Furthermore, the chapters in this thesis have demonstrated that varying binding kinetics 
can have divergent functional effects. For example, in Chapter 4 persistent signaling 
responses were observed for a slowly dissociating GnRH receptor agonist. Conversely, in 
Chapter 5 a positive correlation between potency values and association rate was found for a 
set of NK1 receptor agonists. Additionally, while slow dissociation rates are often thought to 
increase Emax values the opposite was observed with the NK1 receptor agonists. Arguably, 
slowly dissociating agonists could be more efficacious in inducing receptor internalization 
while fastly dissociating agonists are less efficacious in inducing this process, thereby 
maintaining full receptor activation and a higher maximal effect. Lastly, in Chapter 6 it was 
demonstrated that a slowly dissociating NK1 antagonist can significantly decrease the initial 
kinetics of receptor activation. Moreover, these effects were stronger for a slowly associating 
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agonist than for a fastly associating agonist. These results indicate that the signaling kinetics 
can be significantly altered with divergent binding kinetics.  
Altogether, the short review and examples in this thesis could provide a foundation for 
further research towards not only target binding kinetics but also the kinetics involved after a 
ligand is bound to its receptor. Additionally, knowledge of the kinetics of signaling pathways 
could provide more detailed input for mathematical models used to predict the translational 
effects of binding kinetics.  
 
Figure 1: Upon agonist binding to a Gαq coupled receptor, the receptor undergoes a 
conformational change allowing the exchange of GDP to GTP and the time constant (tau) for 
this process ranges from 0.05 to 25 seconds [13-15], followed by activation of the G protein 
(*) within 0.1 to 2 seconds [13, 14, 16]. Following G protein activation, phospholipase C is 
activated with an activation rate of 10 s-1 [17]. Consequently, PLC induces hydrolysis of 
phosphoinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) with a maximum 
production after approximately 0.1 seconds [17, 18]. IP3 can then bind to IP3 receptors which 
results in the opening of Ca2+ channels, releasing Ca2+ into the cytosol within 0.2-0.4 
seconds [19-21]. In turn, Ca2+ induces the activation of myosin light chain kinases (MLCKs) 
with a rate of 1.1 s-1 [22]. Activation of MLCKs will lead to actin contraction after 1-12 
seconds [23, 24].  
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The potential role of binding kinetics in biased signaling  
 
 To date, the concept of biased signaling has gained increasing consideration in the 
GPCR field. Biased signaling or biased agonism can be described by the ability of an agonist 
to selectively activate a specific signaling pathway (Figure 2). For instance, ligand A may 
predominantly activate G proteins (Figure 2A) while ligand B may prefer β-arrestin activation 
(Figure 2B). Concurrently, ligands can also differentiate between different G proteins where 
ligand C could favor Gαi signaling while ligand D could favor Gαq signaling (Figure 2C). 
Biased agonism and its role in GPCR activation has already been extensively studied [25-
27]. Interestingly, a recent publication proposed a new role of ligand-receptor binding kinetics 
in apparent biased agonism [28]. The authors examined the binding kinetics and functional 
effects of several dopamine D2 receptor (D2R) agonists. They were able to correlate 
differential binding kinetics to various biased signaling profiles of D2R agonists. Moreover, it 
was shown that agonist bias could be reversed over time in different cell signaling processes. 
This research article provides a new perspective on binding kinetics and its role in functional 
processes and presents great potential for further research.  
Illustratively, biased signaling at neuropeptide receptors such as the opioid receptor 
family is frequently observed [29-33]. The opioid receptor family consists of three members, 
i.e. δ opioid, κ opioid and μ opioid receptors, the latter being the most studied. For instance, 
Thompson et al. studied the potential for biased agonism of endogenous opioids [34]. They 
reported that several endogenous ligands showed distinct biased signaling profiles in 
comparison to the other endogenous ligands. The binding kinetics of these endogenous 
ligands have not been examined thus far and considering our findings in Chapter 5 it would 
be worthwhile to study the kinetic binding parameters of these ligands. Consequently, it 
should be investigated if the binding kinetics can be correlated with the various signaling 
profiles reported in the study of Thompson et al [34].  
Another neuropeptide receptor that is known for biased signaling is the parathyroid 
hormone receptor type 1 (PTHR1) [35]. Recent studies have proposed that various PTH 
analogs can induce differential signaling pathways. More interestingly, it has been suggested 
that persistent signaling is induced by ligands that prefer G protein-independent pathways 
while ligands that prefer G protein-dependent pathways induce a more transient response 
[36]. Although the binding kinetics of the examined ligands were not reported, the authors did 
briefly discuss the possibility of long residence time being involved in inducing these 
persistent signaling profiles. Similarly, Hothersall et al. recently reviewed the role of 
residence time in sustained signaling profiles [37] which agreed with our findings in Chapter 
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4. To test if long residence time is involved in persistent signaling profiles, the binding 
kinetics of PTH analogs should be examined.  
In conclusion, specific knowledge of how ligand binding kinetics can influence biased 
profiles of agonists for neuropeptide receptors, and GPCRs in general, could improve the 
discovery of novel drugs targeting this receptor family. 
 
Figure 2: Schematic overview of various types of biased agonists. Upon agonist binding, 
biased agonism can be observed towards G protein activation (A), β-arrestin activation (B) 
or a specific G protein subtype, such as Gαs (C).   
 
The future of binding kinetics at neuropeptide receptors  
 Neuropeptide receptors present an attractive drug target in the treatment of a wide 
range of therapeutic areas such as cancer, inflammation and reproduction [38]. In view of the 
latter, this receptor family is well-known for its role in the hypothalamic-pituitary-gon adal 
axis, playing a crucial role in reproductive functions. Over the past decade, kisspeptin and its 
receptor KISS1R (also known as GPR54) have gained interest in the treatment of sex 
hormone-dependent disorders such as infertility and precocious puberty [39]. More 
interestingly, increasing evidence indicates the benefits of long-acting kisspeptin analogues 
targeting KISS1R [39-43]. While current research is mainly focused on increasing the 
metabolic and plasma half-life of KISS1R ligands, another approach could be to design drugs 
with slow dissociation kinetics. It would be interesting to examine the binding kinetics of 
kisspeptin and its analogues and establish a structure-kinetics relationship (SKR) study with 




This thesis evolves around the kinetic binding interactions between the endogenous 
ligand, the drug and the receptor followed by the cellular response. Three main conclusions 
are drawn;  
1) Both kinetic binding assays such as radioligand binding and TR-FRET studies, and 
kinetic functional assays such as real-time cAMP and real-time morphology studies, 
are very suitable to qualitatively and quantitatively study the binding kinetics of 
numerous ligands.  
2) The binding kinetics of endogenous neuropeptides are very divergent. 
3) Differential binding kinetics will translate into differential functional effects in vitro.  
In conclusion, the toolbox of kinetic assays is expanding which allows more accessible 
and high-throughput measurements of binding kinetics. Secondly, these kinetic assays 
enable the assessments of kinetic binding parameters of endogenous ligands and drug 
candidates. Lastly, including kinetic binding studies in the drug discovery paradigm will 
improve the understanding of drug-target interactions, translation to functional effects and 
predictions of in vivo responses.  
Finally, I am hopeful that this thesis will contribute to an increased understanding of 
ligand-receptor interactions and that it provides a larger toolbox suitable for studying these 
kinetic interactions. My ambition is to transform binding kinetics into traditional, 
indispensable, drug discovery parameters and thereby improve the success rate of drug 
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In this thesis, the kinetic binding parameters of endogenous ligands and drug 
candidates and their effect on signal transduction are examined to provide a better 
understanding of drug-target interactions. While drug discovery programs are traditionally 
focused on equilibrium-based parameters such as affinity values, drug candidates often fail 
in clinical trials due to on and/or off target toxicity and/or lack of in vivo efficacy. In the past 
decade, drug-target binding kinetics, i.e. association and dissociation rate constants, are 
increasingly acknowledged as better predictive parameters of in vivo drug action and it is 
proposed to incorporate these parameters to decrease drug attrition rates and improve the 
drug discovery paradigm. To investigate the role of binding kinetics in ligand-receptor 
interactions, two G protein-coupled receptors (GPCRs) are used as model systems, namely 
the gonadotropin-releasing hormone (GnRH) receptor and the neurokinin 1 (NK1) receptor. 
Both receptors can be categorized in the neuropeptide receptor family and this receptor 
family plays a crucial role in the peripheral and central nervous system making them 
interesting targets in therapeutic areas such as epilepsy, pain and psychological disorders. 
An in-depth background on neuropeptide receptors, binding kinetics and kinetic assays is 
provided in Chapter 1.    
Since drug candidates often compete with endogenous ligands in the body, more 
knowledge on the interactions between endogenous ligand and receptor could aid in 
understanding desired (kinetic) interactions of a drug candidate with that receptor. In 
Chapter 2, novel insights into the kinetic profile of endogenous neuropeptides and their 
receptors are considered. The binding kinetics, internalization kinetics and release kinetics of 
three exemplary neuropeptide-receptor pairs are reviewed and these kinetic parameters 
proved to be quite variable. Collectively, this review provides a perspective for future drug 
research to include the kinetic profile of the target receptor and its endogenous ligand(s). 
This will improve the understanding of desired drug-target binding kinetics and thus lead to 
more efficacious drugs.   
One of the challenges in examining binding kinetics is the lack of robust kinetic 
assays suitable to study these kinetic binding parameters. To overcome this hurdle, a 
selection of well-known GnRH receptor drugs is used to design and validate kinetic 
radioligand binding and TR-FRET protocols in Chapter 3. A competition association assay is 
designed for both kinetic assays and this facilitated the determination of the kinetic binding 
parameters of 12 unlabeled GnRH analogs. Both affinity values and values of dissociation 
rate constant are highly correlated between both kinetic assays. Additionally, the association 
and dissociation rate constants of the tested GnRH drugs are very divergent, indicating a 
pivotal role of binding kinetics in drug-target interactions. This research provides new 
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perspectives by incorporating kinetic binding parameters in current research which could 
potentially improve future drug discovery targeting the GnRH receptor.   
The functional effects of two kinetically diverse GnRH agonists, i.e. GnRH and 
buserelin, from Chapter 3 are further studied in Chapter 4. A morphology-based real-time 
assay is found to be suitable for studying receptor-mediated responses. Persistent signal 
transduction profiles are observed for both agonists. However, wash-out experiments prove 
that the persistent signaling profile of fastly dissociating GnRH is most likely due to ligand 
rebinding while the persistent signaling profile of slowly dissociating buserelin is presumably 
due to a long-lasting receptor binding profile. This study stresses the impact of slow 
dissociation rates for long-lasting receptor activation and could support future research 
towards drugs with prolonged efficacy.  
In Chapter 5, another well-known neuropeptide receptor is examined, namely the 
NK1 receptor. Considering the importance of knowledge of the binding kinetics of not only 
drug candidates but endogenous ligands discussed in Chapter 2, the association and 
dissociation rate constants of endogenous tachykinins and a few close analogs are 
examined. Interestingly, the binding kinetics of the tested tachykinins are very diverse, 
particularly the association rates. Furthermore, kinetic binding parameters are highly 
correlated to signal transduction values such as in vitro potency and maximal response 
values. Our findings demonstrate the great variability in binding kinetics of these tachykinins 
and underline the importance of measuring the kinetic binding parameters of not only drug 
candidates but also endogenous ligand(s).  
Chapter 6 is focused on elucidating the missing link between binding kinetics and 
signal transduction to improve the understanding of drug action in vivo. The effects of two 
NK1 receptor antagonists with variable dissociation rates are examined using two 
endogenous tachykinins with variable association rates. We found that the divergent kinetic 
profiles of both antagonists and endogenous agonists resulted in different signal transduction 
profiles. Moreover, these findings are consistent throughout multiple assay formats, cellular 
backgrounds and mathematical simulations. This research emphasizes that knowledge of the 
relationship between drug-target binding kinetics and cellular responses is important for 
improved understanding of drug efficacy.    
In summary, multiple kinetic binding assays (i.e. radioligand binding and TR-FRET 
studies) and kinetic functional assays (i.e. real-time cAMP and real-time morphology studies) 
are designed and validated to study binding kinetics and their role in signal transduction of 
numerous endogenous ligands and drug candidates. Significant differences in the kinetic 
profiles of endogenous neuropeptides and well-known drugs are observed and this kinetic 
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variability triggered differential functional effects in vitro. These overall conclusions are 
discussed in Chapter 7. Finally, the findings in this thesis could contribute to a larger toolbox 
suitable for studying kinetic ligand-receptor parameters. Moreover, knowledge of the kinetic 
binding parameters of drugs and endogenous ligands could play a pivotal role in 
















In dit proefschrift zijn de kinetische bindingparameters van endogene liganden en 
potentiële geneesmiddelen en hun effect op signaaltransductie onderzocht, om een beter 
inzicht te krijgen in geneesmiddel-receptor interacties. Geneesmiddelonderzoek 
programma’s zijn voornamelijk gericht op evenwichtsparameters zoals affiniteit, maar 
potentiële geneesmiddelen stranden vaak in klinische onderzoeken door toxiciteit en/of een 
gebrek aan in vivo effectiviteit. In het afgelopen decennium wordt geneesmiddel-
receptorkinetiek meer en meer gezien als een parameter die de in vivo geneesmiddelwerking 
beter kan voorspellen. Het verdient derhalve aanbeveling om deze kinetische 
bindingsparameters op te nemen in geneesmiddelonderzoeksprogramma’s om het hoge 
percentage mislukkingen terug te dringen. Om de rol van bindingskinetiek in ligand-receptor 
interacties te onderzoeken zijn twee G-eiwit gekoppelde receptoren (GPCRs) gebruikt als 
modelsysteem, namelijk de gonadotropine-vrijgevend hormoon (GnRH) receptor en de 
neurokinine 1 (NK1) receptor. Beide receptoren vallen onder de neuropeptide receptorfamilie 
en deze receptorfamilie speelt een belangrijke rol in het perifere en centrale zenuwstelsel. Dit 
maakt deze receptorfamilie een aantrekkelijk aangrijpingspunt in therapeutische gebieden 
zoals epilepsie, pijn en psychologische aandoeningen. Een grondig overzicht van 
neuropeptide receptoren, bindingskinetiek en kinetische bepalingsmethoden wordt gegeven 
in Hoofdstuk 1.  
Potentiële geneesmiddelen zijn vaak in competitie zijn met endogene liganden. 
Daarom is het van belang om meer kennis van de interacties tussen endogene liganden en 
de receptor te verkrijgen. Dit kan helpen bij het beter begrijpen van gewenste (kinetische) 
interacties tussen een potentieel geneesmiddel en de receptor. In Hoofdstuk 2 worden 
nieuwe inzichten in het kinetische profiel van endogene neuropeptiden en hun receptoren 
behandeld. Uit een literatuurstudie van bindingskinetiek, receptor internaliseringskinetiek en 
ligand uitscheidingskinetiek voor drie voorbeelden van neuropeptide-receptor combinaties 
bleek dat de kinetische profielen van deze drie combinaties erg verschillend zijn. 
Samengevat geeft deze literatuurstudie aan dat het introduceren van het kinetische profiel 
van de receptor en z’n endogene ligand(en) tot een verbetering in het begrip van de 
gewenste bindingskinetiek van het potentiële geneesmiddel kan leiden. Dit kan dus 
resulteren in effectievere geneesmiddelen.  
Eén van de uitdagingen in het onderzoeken van bindingskinetiek is het gebrek aan 
robuuste proeven die geschikt zijn voor het bestuderen van kinetische parameters. Om meer 
kinetische proeven beschikbaar te maken is een selectie van bekende GnRH receptor 
geneesmiddelen gebruikt om kinetische radioligand binding en TR-FRET (fluorescentie) 
studies op te zetten en te valideren in Hoofdstuk 3. Een competitieve associatie proef werd 
ontworpen voor beide kinetische proeven en hiermee konden de kinetische parameters van 
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twaalf GnRH geneesmiddelen bepaald worden. Zowel de affiniteit als de dissociatie 
snelheidswaardes kwamen goed overeen in de twee verschillende kinetische 
bepalingsmethoden. De associatie- en dissociatiesnelheden van de 12 GnRH 
geneesmiddelen waren erg verschillend, wat een belangrijke rol kan spelen in geneesmiddel-
receptor interacties. Dit onderzoek heeft derhalve nieuwe kinetische perspectieven gegeven 
op bekende GnRH geneesmiddelen. Het meenemen van kinetische bindingsparameters kan 
toekomstige geneesmiddel onderzoek voor de GnRH receptor verbeteren.  
De functionele effecten van twee kinetisch diverse GnRH agonisten, GnRH en 
busereline, uit Hoofdstuk 3 zijn verder bestudeerd in Hoofdstuk 4. Een op morfologie-
gebaseerde proef bleek erg geschikt voor het meten van receptor-gemedieerde responsen. 
Aanhoudende signaleringsprofielen werden waargenomen voor beide agonisten. Was-
experimenten proeven toonden aan dat de aanhoudende signalering van snel dissociërend 
GnRH toe te schrijven was aan het opnieuw binden van de agonist aan de receptor. De 
aanhoudende signalering van langzaam dissociërend busereline werd hoogstwaarschijnlijk 
veroorzaakt door langdurige receptorbinding. Deze bevindingen leggen nadruk op de impact 
van een langzame dissociatiesnelheid op langdurige receptoractivatie. Dit kan toekomstig 
onderzoek naar geneesmiddelen met een lange werkingsduur bevorderen.  
In Hoofdstuk 5 wordt een andere welbekende neuropeptide receptor beschreven, 
namelijk de NK1 receptor. Het belang van kennis van de bindingskinetiek van niet alleen 
toekomstige geneesmiddelen, maar ook endogene liganden is al besproken in Hoofdstuk 2. 
Daarom zijn de associatie- en dissociatiesnelheidsconstanten van endogene tachykinines en 
een aantal vergelijkbare analogen onderzocht. Het was opmerkelijk dat de bindingskinetiek 
van de onderzochte tachykinines erg verschillend was, met name de associatie snelheden. 
Bovendien correleerden de kinetische bindingsparameters zeer goed met het maximale 
effect en ‘potency’ waarden in vitro. Deze resultaten tonen grote verschillen aan in de 
bindingskinetiek van endogene tachykines en benadrukken het belang van het meten van 
bindingskinetiek voor niet alleen potentiële geneesmiddelen, maar ook de endogene 
liganden waarmee zij in competitie zijn.  
Hoofdstuk 6 is gericht op het ophelderen van de ontbrekende schakel tussen 
bindingskinetiek en signaaltransductie, om het begrip van geneesmiddel werking in vivo te 
verbeteren. De effecten van twee NK1 receptor antagonisten met variabele dissociatie 
snelheden werden onderzocht in combinatie met twee endogene tachykinines met variabele 
associatie snelheden. We toonden aan dat diverse kinetische bindingsprofielen van zowel 
antagonisten als endogene agonisten, tot verschillende signaaltransductieprofielen kunnen 
leiden. Deze resultaten waren consistent onder verschillende proef condities, cellulaire 
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achtergronden en in wiskundige modellen. Dit onderzoek toont aan dat kennis van de 
wisselwerking tussen bindingskinetiek en cellulaire responsen belangrijk is voor een 
verbeterd begrip van geneesmiddel effectiviteit.  
Samenvattend, meerdere kinetische bindingsproeven (zoals radioligand binding en 
TR-FRET studies) en kinetische functionele proeven (zoals cAMP en morfologie studies) 
werde ontworpen en gevalideerd. Hiermee is de bindingskinetiek en de rol daarvan in 
signaaltransductie van verschillende endogene liganden en potentiële geneesmiddelen 
onderzocht. Significante verschillen in de kinetische profielen van endogene neuropeptiden 
en bekende geneesmiddelen werden waargenomen en deze verschillen zorgden ook voor 
variabele functionele effecten in vitro. Deze conclusies zijn besproken in Hoofdstuk 7. De 
bevindingen besproken in dit proefschrift kunnen bijdragen aan een uitgebreid 
instrumentarium, geschikt voor het onderzoeken van kinetische ligand-receptor interacties. 
Kennis van de kinetische bindingsparameters van potentiële geneesmiddelen en endogene 
liganden kan een belangrijke rol spelen in het ophelderen van ligand-receptor interacties en 
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